预约演示
更新于：2026-01-17
Relatlimab
瑞拉利单抗
更新于：2026-01-17
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2025-05-30), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 9503097L
来源: *****
Sequence Code 523986643H
来源: *****
关联
63
项与 瑞拉利单抗 相关的临床试验NCT06999980
A Phase II, Multicentre, Parallel Group, Open Label, Randomised Clinical Trial of Neoadjuvant Nivolumab and Ipilimumab Combined With Relatlimab for Patients With Resectable Advanced Melanoma Identified as Poor Responders to Immunotherapy
This clinical trial is for patients with stage 3 cutaneous melanoma and patients with mucosal melanoma who are able to have surgery to remove all tumour deposits. To improve the chance that melanoma will not recurr, new experimental combinations of a type of treatment called immunotherapy will be given before surgery.
开始日期2026-01-01 |
申办/合作机构 |
NCT06816927
A Multi-Center, Randomized, Phase 2 Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (GIANT)
GIANT is an open-label, multi-center, randomized, perioperative (neoadjuvant followed by adjuvant), phase 2 trial with a safety lead-in phase to investigate the feasibility, safety and tolerability, and establish the biological activity of nivolumab with or without relatlimab in patients with isocitrate dehydrogenase (IDH) wildtype newly diagnosed glioblastoma (ndGBM).
开始日期2025-11-28 |
申办/合作机构 |
NCT06683755
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
To determine the recommended Phase IIa dose (RP2D) of the triplet combination.
To determine the safety and efficacy of the combination at the RP2D.
To determine the safety and efficacy of the combination at the RP2D.
开始日期2025-05-01 |
100 项与 瑞拉利单抗 相关的临床结果
登录后查看更多信息
100 项与 瑞拉利单抗 相关的转化医学
登录后查看更多信息
100 项与 瑞拉利单抗 相关的专利（医药）
登录后查看更多信息
125
项与 瑞拉利单抗 相关的文献（医药）2026-01-01·EUROPEAN JOURNAL OF CANCER
Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)
Article
作者: Pat, Karin ; Bölükbas, Servet ; Baas, Paul ; Ploenes, Till ; Maes, Brigitte ; Vanbockrijck, Michel ; Hartemink, Koen ; Cuppens, Kristof ; Wiesweg, Marcel ; Aigner, Clemens ; Du Pont, Bert ; Theegarten, Dirk ; Doerr, Fabian ; Schuler, Martin
BACKGROUND:
Preoperative immunotherapy targeting PD-1/-L1 with chemotherapy induces histopathological responses and improves survival in patients with resectable non-small cell lung cancer (NSCLC). NEOpredict-Lung (NCT04205552) established the feasibility of dual blockade of PD-1 and LAG-3 immune checkpoints prior to curatively intended resection. Here we report extended follow-up, postoperative treatments and patterns of response and recurrence.
PATIENTS AND METHODS:
Patients with resectable NSCLC (stages IB-IIIA) were randomized to receive two doses nivolumab (240 mg, arm A) with or without relatlimab (80 mg, arm B) every 2 weeks. Overall and disease-free survival (OS, DFS) rates, response and recurrence patterns and subsequent therapies were evaluated.
RESULTS:
60 patients were enrolled from March 2020 to July 2022. The present analysis was conducted per December 2024 with a median follow-up of 37.4 months. 45 patients were alive without disease recurrence,15 patients recurred (4 locoregional and 11 metastatic), and 7 patients died. The 3-year OS and DFS rates were 88.4 % and 73.3 % in arm A and 88.9 % and 60.3 % in arm B. Patients achieving major pathological response (≤10 % viable tumor cells in resected NSCLC) trended towards better DFS (HR 0.35; 95 % CI, 0.1-1.19). Downstaging was confirmed in 53.3 % of patients in arm A and in 66.7 % of patients in arm B. Nodal downstaging occurred in 28.6 % of patients with nodal disease in arm A and in 66.7 % of patients in arm B.
CONCLUSIONS:
Short course preoperative nivolumab with or without relatlimab showed encouraging efficacy and survival outcomes, which compare favorably with chemo-immunotherapy-based perioperative treatment regimens.
2026-01-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Discovery and validation of LAGi-DEL: A nanomolar LAG-3 inhibitor that reverses immune suppression in tumor-immune co-culture models
Article
作者: Calvo-Barreiro, Laura ; Abdel-Rahman, Somaya A ; Nada, Hossam ; Gabr, Moustafa T
Lymphocyte activation gene-3 (LAG-3) is an immune checkpoint receptor that drives T cell exhaustion and tumor immune evasion. While antibody-based LAG-3 inhibitors have entered clinical practice, their poor tumor penetration, high manufacturing costs, and prolonged half-lives limit dosing flexibility and can lead to extended immune-related toxicities. Potent small molecule LAG-3 inhibitors remain elusive, leaving a major gap in the immuno-oncology landscape. Here, we report the discovery of LAGi-DEL, the first nanomolar small molecule LAG-3 inhibitor, identified through screening a 4.2-billion compound DNA-encoded chemical library (DEL). LAGi-DEL binds directly to LAG-3 with a Kd of 97 nM (SPR) and 271 nM (MST) and disrupts the LAG-3/MHC-II interaction with an EC50 of 138 nM, the highest potency reported for a small molecule against LAG-3. Molecular docking and dynamics simulations reveal that LAGi-DEL induces stabilizing conformational changes within the LAG-3 binding pocket. Functionally, LAGi-DEL restores T cell activation, elevates IFN-γ secretion, and promotes immune-mediated killing in acute myeloid leukemia and lung cancer co-culture models, matching the efficacy of the FDA-approved antibody relatlimab. Pharmacokinetic profiling shows favorable drug-like properties, including high solubility, acceptable permeability, robust metabolic and plasma stability, low cytotoxicity toward normal cells, and negligible hERG and CYP liabilities. These attributes, combined with broad functional activity and unprecedented potency, position LAGi-DEL as a promising scaffold for developing orally available LAG-3 inhibitors and as a blueprint for next-generation immune checkpoint therapeutics.
2025-12-31·Melanoma Management
Patient preferences for stages II–IV melanoma treatments in the UK: results from a cross-sectional study
Article
作者: Noval, Alejandro ; Cairns, Grant ; Guillaume, Xavier ; Vekeria, Shital ; Sadou, Amal ; Vaz, Luis ; Moussallem, Alissar
AIM:
To understand patient preferences for treatment attributes in adjuvant and metastatic melanoma in the UK.
MATERIALS AND METHODS:
Patients with stages II-IV melanoma completed an online survey from November 2022 to February 2023 comprising two discrete choice experiments (DCE) exploring efficacy, safety, and dosing regimen.
RESULTS:
Out of 104 respondents, 100 and 102 patients completed DCEs for adjuvant (Adj-DCE) and metastatic (Met-DCE) settings, respectively. 4-year relapse-free survival (RFS) for Adj-DCE (33%), and 4-year overall survival (OS) for Met-DCE (40%) had the highest relative attribute importance (RI), followed by risk of grade ≥3 adverse events (29% versus 26%, respectively). Patients with advanced melanoma or BRAF mutation had significantly higher RI for RFS and OS.
CONCLUSION:
Patients, especially those with advanced melanoma or BRAF mutation, perceive efficacy as the most important factor in determining choice of treatment.ARTICLE HIGHLIGHTSIn the UK, melanoma is the 5th most common cancer with around 19,921 newly diagnosed cases in 2022. Fortunately, treatment options for patients with melanoma have expanded significantly over the past few years. Each of these new therapies carries a different benefit-to-risk profile and varies with regard to different aspects of patient convenience.The aim of this study was to understand patient preferences for adjuvant and metastatic treatment attributes in stage II/III and stage IV melanoma in the UK and to determine predictive factors for treatment preferences in different subpopulations.A discrete-choice experiment (DCE) was conducted via an online quantitative treatment preference survey to elicit patients' relative preferences for treatment attributes, including safety, dosing regimen, and efficacy for adjuvant and metastatic settings, respectively.Analysis of the DCE data using Hierarchical Bayesian (HB) model revealed distinct preferences among the 104 survey respondents.Efficacy, as assessed by 4-year RFS in the adjuvant setting and 4-year OS in the metastatic setting, was the most important attribute, followed by severe adverse events (AEs) and dosing regimen.Immune checkpoint inhibitors (ICI) were consistently ranked as the preferred options across all patient segments. Based on the hypothetical drug profile presented in the DCE, the fixed dose combination of nivolumab and relatlimab was the preferred regimen in the metastatic disease setting while either pembrolizumab or nivolumab were preferred in the adjuvant setting.Our study highlights the importance of considering patients' prioritization of treatment efficacy as the primary factor when making decisions about melanoma care, both in the adjuvant and metastatic settings. Although efficacy and safety were attributed to have relatively similar importance for treatment preference in the adjuvant setting, patients with more advanced disease or those carrying the BRAF mutation placed heightened emphasis on treatment efficacy.
192
项与 瑞拉利单抗 相关的新闻（医药）2026-01-15
·贝壳社
▲点击图片，了解详情
作者：贝壳社
2026年，转型与产出的关键之年。
作为全球生物医药行业的“风向标”，在2026年JMP大会上，礼来、默沙东、罗氏、诺华、赛诺菲、武田、再生元、百济神州等巨头披露的企业动态和战略布局对行业具有深刻的启发意义。
整体来看，赛道呈现出极致分化态势，ADC与GLP-1被视为为未来五年的重要增长引擎，头部企业正通过组合疗法和给药迭代修筑护城河。mRNA、siRNA及放射性配体疗法（RLT）从“前沿概念”转向“临床常态”，MNC开始整合这些技术平台。BD策略精准化，2025年完成的中小规模“补强型”收购开始步入兑现期，2026年的并购逻辑将更加多元化。
1
热点赛道动态：技术迭代与适应症拓展双轮驱动
ADC依然是肿瘤板块的主角之一。
默沙东通过与第一三共的深度协作，全面推进I-DXd、P-DXd及sac-TMT（TROP2ADC）等资产，通过多靶点布局拓展ADC在多种肿瘤领域的应用。百济神州将ADC视为核心技术模态之一，并在全球范围内积极推动药物可及性，加速ADC管线迭代。礼来在2025年完成了多项ADC相关的技术交易，旨在提升其在肿瘤治疗领域的技术能力和产品管线。
减重市场正从单纯的体重降低竞争，转向代谢综合征的全面管理。
礼来的策略不仅限于Zepbound，更在于通过AI驱动的药物发现和LillyDirect直接面向患者的模式，构建代谢领域的闭环生态。罗氏通过收购Carmot Therapeutics，获得了CT-388和CT-996等在研药物资产。再生元利用其遗传学中心（RGC）的大数据优势，通过siRNA等新技术探索新型代谢疗法。
双抗与免疫疗法在于精细化免疫调节。赛诺菲的核心资产Dupixent（度普利尤单抗）持续扩张适应症（如慢性自发性荨麻疹CSU等），同时大力推进amlitelimab（OX40L单抗）和frexalimab（CD40L单抗）等自免管线，旨在建立更精准、更安全的免疫治疗新标准。BMS的nivolumab+relatlimab固定剂量组合正向一线非小细胞肺癌（NSCLC）和黑色素瘤等领域渗透。罗氏则继续利用其双抗平台开发针对神经科学（如阿尔茨海默病）和眼科疾病的新药。
GCT与mRNA方面，2026年是莫德纳实现财务框架转型的关键年。公司预计2026年收入增长可达10%，并依托mNEXSPIKE等季节性呼吸道疫苗及肿瘤新抗原疫苗（INT）管线，目标在2028年实现现金流平衡。
2
重点企业战略规划：核心赛道深耕与平台化布局并行
礼来以“肥胖新纪元”和“AI制药革命”为核心战略成为大会焦点。肥胖领域，用“迭代管线+补充产能+扩大准入+创新支付”四维策略构建全链条布局。AI布局上，与英伟达合作，未来五年投入最高10亿美元共建AI联合创新实验室，聚焦药物发现和开发全流程的AI赋能，利用英伟达的AI芯片和技术，加速药物研发进程。
辉瑞通过BD整合+AI全应用，冲刺2030增长目标。辉瑞2026年聚焦四大任务：最大化核心交易价值（累计BD投入800亿美元，三大交易占80%）、实现研发里程碑、布局2028年后增长、全业务链应用AI。核心赛道上，PD1/VEGF双抗推进4项III期研究，肥胖领域瞄准2030年1500亿美元市场；AI贯穿全环节提升效率与精度。此外，通过License-in补强管线，彰显“内生研发+外部并购”的增长逻辑。
安进以“技术向新”为战略，加速生物技术与AI融合。收购Horizon Therapeutics补强罕见病管线；AI布局上，与英伟达等合作。核心产品持续放量，GLP-1药物有优势，部分产品将在中国上市。同时，深化与中国本土企业合作。
诺华通过平台化布局，规避专利悬崖风险。诺华专注四大疾病领域，搭建五大技术平台，有9款销售峰值超十亿美元产品，未来几年将推8款新药。研发上，推进12项潜在注册数据，收购完善xRNA疗法布局。
BMS以BD为核心，构建多领域增长引擎。BMS将2026年BD作为资本配置首要任务，过去两年完成300亿美元交易，未来将持续并购以补强管线。其目标是到2030年推出10多款新药，重点布局神经科学、心血管、免疫学和肿瘤学等领域。AI应用上，将机器学习融入临床开发与患者筛选提升研发效率。
百济神州以产品放量+管线深耕，冲刺全球生物制药巨头。核心产品泽布替尼2024年Q3全球销售额达74.23亿元，同比增长51.0%，2026年有望达260亿元全年销售规模；替雷利珠单抗已在全球47个市场获批，16个市场纳入报销，预计2026年下半年在日本获胃癌一线治疗批准。公司依托“自主研发+全球合作”模式，加速新兴赛道布局，进一步巩固竞争力。
3
BD趋势：赛道补强与生态协同成核心逻辑
2025-2026年医药行业并购集中于ADC、双抗等热点领域，头部企业通过并购快速获取核心资产与技术平台。诺华收购Avidity Biosciences，获取肌肉疾病xRNA疗法管线；安进收购Horizon Therapeutics，拓展罕见病领域布局；赛诺菲收购Blueprint，补强肿瘤管线。
跨国制药巨头（BigPharma）从“规模扩张”转向“管线重塑”。面对即将到来的2026-2030年“专利悬崖”，大药企的焦点较为集中。如并购（M&A）紧迫感，Merck、BMS和强生等企业为避免营收断崖，巨头们将现金流优先用于收购后期临床资产，以快速补充管线。渤健的“New Biogen”愿景体现了其业务转型的战略方向。
全球制药巨头正通过ADC、GLP-1激动剂、GCT及双特异性抗体等创新平台，积极构建第二增长曲线，以应对专利到期带来的市场挑战。这意味着，到2026年，具备“即刻进入Phase3”潜力的中后期资产将比早期实验室资产更具溢价优势。
相比于往年的盲目扩张，后续的BD更注重技术平台的垂直整合，形成跨领域创新生态。礼来与英伟达合作建设AI制药联合实验室，五年投入10亿美元；赛诺菲与华深智药旗下EarendilLabs升级战略合作，总价值达25.6亿美元，聚焦AI驱动的双特异性抗体优化；安进与英伟达、PostEra等合作，借助AI工具加速疗法开发。平台型合作聚焦于技术互补，可降低研发成本，同时实现从靶点发现至商业化的全链条协同，成为行业创新的重要模式。
4
生物医药行业展望
根据市场分析，2026-2030年医药行业将进入“创新收获期”，其中GLP-1类药物（如减肥、降糖）正从单纯的治疗药物演变为综合代谢管理平台。例如，2024年礼来的替尔泊肽年销售额已达到165亿美元，而诺和诺德的司美格鲁肽更是达到了293亿美元。预计到2030年，中国GLP-1受体激动剂类减重药的市场规模将达到383亿元左右。辉瑞、罗氏、再生元等公司都在加大投入，未来的竞争点将在于：更长的药效周期（如月结、季度结）；更少的副作用（肌肉流失控制）；更广泛的适应症（心血管、非酒精性脂肪肝等）。
前沿疗法的商业化“奇点”正在到来，细胞与基因疗法（CGT）和RNA疗法（如Alnylam的2030愿景）正通过技术创新和模式变革，逐步突破生产成本和报销瓶颈。随着传奇生物等企业有望在2026年实现盈利，规模化生产与支付创新正在成为该领域的关键发展方向。
目前，生物医药行业已经告别了纯粹的资本泡沫，回归到“以数据为王、以临床价值为准”的本质。
技术层面，ADC、GLP-1、RNAi与GCT分别在实体瘤治疗、代谢领域和慢性病治疗中展现出巨大的技术潜力和临床价值。战略层面，面对专利悬崖，多元化布局成关键。投资层面，2026年将是临床成功的“大年”，数据的优劣将直接决定企业估值的重新排位。
对中国医药企业而言，2026年将是“借船出海”与“同台竞技”的关键时刻。无论是ADC的技术授权，还是在双抗领域的创新突破，只有真正具备临床差异化的产品，才能在全球化的浪潮中占据一席之地。
往
期
推
荐
1
医健企业前沿动态
2
医健行业BD/出海/投融资洞察
_
_
_
*声明：本文仅用于分享，不构成任何投资建议，且非治疗方案推荐。
素材来源官方媒体/网络新闻
关于贝壳社
贝壳社（Bioclub）是国内领先的医健创新创业服务平台。构建了"产业空间+创业培育+投资孵化+资本赋能"四位一体服务体系，为医健领域创业企业提供全周期赋能。通过深度挖掘高成长项目、精准匹配产业资源及全球化生态网络，覆盖企业从孵化培育到加速发展的全链路，重点提供包括空间落地、创业培育、资本运作及跨境资源链接服务。贝壳社以加速科学技术成果转化与产业升级为目标，致力于成为医健领域的孵化器、加速器、连接器。
并购抗体药物偶联物信使RNA疫苗免疫疗法
2026-01-05
免疫检查点LAG-3的
功能机制与临床应用
Molecular mechanisms and clinical applications
of the immune checkpoint LAG-3
亮点速览
在免疫检查点抑制剂疗法深刻改变肿瘤治疗格局的今天，PD-1/CTLA-4通路的成功也揭示了其局限性：响应率不足与耐药问题普遍存在。寻找下一代的治疗靶点，已成为领域核心挑战。
淋巴细胞活化基因-3（LAG-3）作为继CTLA-4和PD-1之后，第三个经FDA批准上市的免疫检查点，其重要性日益凸显。它并非PD-1的简单替代，而是一个拥有独特结构、新型配体和独立信号通路的关键调控分子。对LAG-3机制的深入理解，正为我们提供克服现有治疗瓶颈的新视角与武器。
上海科技大学王皞鹏教授团队在最新发表的述评中为您解析LAG-3靶向治疗的三大前沿进展：
1
机制新解：从“配体竞争”到“信号解离”的范式转变
2
信号破译：泛素化修饰作为核心“功能开关”
3
临床进阶：从联合验证走向精准分层
王皞鹏
上海科技大学
王皞鹏 昌平实验室领衔科学家、上海科技大学长聘副教授、清华大学免疫研究所兼聘教授。长期聚焦于肿瘤免疫治疗，获国家自然科学基金委员会青年科学基金项目（A类）（原国家杰出青年科学基金项目），入选国家高层次人才。国家重点研发计划“合成生物学重点专项”专家组成员，中国生物医药产业链创新与转化联盟免疫治疗药物分会副主任委员，中国细胞生物学学会细胞与基因治疗分会和免疫细胞生物学分会委员，中国生物化学与分子生物学会分子免疫学专业分会委员，中国抗癌协会肿瘤代谢专业委员会委员。近年来以通信（含共同通信）作者在Cell、Immunity、Cell Res、Nat Struct Mol Biol、Dev Cell等高影响力期刊发表研究成果；也应邀为Nat Metab、Cell Stem Cell、Cell Res、Immunol Rev、Trends Cancer等权威杂志撰写免疫治疗综述及评述。
Abstract
摘 要
淋巴细胞活化基因-3（LAG-3，又称CD223），在调控T细胞功能和维持免疫稳态中发挥关键作用，被公认为继程序性死亡蛋白-1（PD-1）和细胞毒性T淋巴细胞抗原-4（CTLA-4）之后最具潜力的共抑制性免疫检查点。LAG-3在活化的T细胞和肿瘤微环境中的耗竭性T细胞（TEX）表面高表达，其抑制功能是肿瘤逃逸免疫监视的关键机制。与PD-1和CTLA-4相比，LAG-3在调控T细胞受体（TCR）信号强度、限制T细胞增殖及效应因子分泌方面具有独特的作用模式，因此被普遍认为是继PD-1和CTLA-4之后最具临床开发潜力的免疫检查点靶点之一。近年来，随着对LAG-3分子结构、胞外区配体相互作用[如主要组织相容性复合体Ⅱ类分子（MHCⅡ类分子）、纤维蛋白原样蛋白1（FGL1）等]以及胞内信号转导机制认识的不断深入，多种靶向LAG-3的单克隆抗体已进入临床研究阶段，并在与PD-1抑制剂联合治疗中显示出良好的应用前景。本文将系统地总结并探讨LAG-3的分子结构、配体相互作用和信号通路的分子机制，以及其靶向药物和临床疗法的最新研究进展和应用前景，旨在为LAG-3靶向疗法的深入研究和未来临床策略优化提供有力的参考。
CJCB20251201
扫码获取完整全文
LAG-3的结构与配体
1.1 LAG-3结构
LAG-3是一种Ⅰ型跨膜糖蛋白，分子量约为50 000，包含525个氨基酸残基。该基因编码位于12号染色体p13.32区域，与同样位于12号染色体的CD4基因显示出结构同源性。LAG-3蛋白结构包括胞外区、跨膜区和胞内区三个主要部分。
LAG-3的胞外区由四个免疫球蛋白（Ig）样结构域（D1、D2、D3、D4）构成。其中D1结构域与CD4的D1结构域具有约20%的氨基酸序列同源性，是LAG-3结合MHC的关键区域。D1结构域中包含独特的、富含脯氨酸的“额外环状结构”（extra loop），该结构（特别是Pro111位点）被证实赋予LAG-3对其主要配体MHCⅡ类分子极高的亲和力，其亲和力比CD4高。
跨膜区由疏水性氨基酸组成，将LAG-3锚定于细胞膜上。LAG-3跨膜区在序列上缺乏CD4跨膜区所具备的保守半胱氨酸或组氨酸残基，从而无法与LCK形成共价或非共价关联，这种结构上的不关联，使LAG-3可能通过与TCR-CD3复合体结合，主动驱动共受体（如CD4/CD8）与LCK的解离，进而发挥其信号抑制作用。这一关键结构特征提示LAG-3抑制性功能所依赖的非经典性信号转导机制。
LAG-3在T细胞表面发挥抑制功能的活性形式与其寡聚化状态密切相关。早期研究推测LAG-3可能通过D1结构域进行二聚化或形成更高阶的聚集体，但这一观点已被后续的结构生物学新发现所修正。对人源LAG-3胞外区的晶体结构解析，明确了其二聚化界面并非位于配体结合的D1结构域，而是定位于胞外区的D2结构域，这一发现排除了MHCⅡ类分子结合与LAG-3寡聚化直接相关的假设。进一步针对小鼠糖基化LAG-3的高分辨率结构分析发现，LAG-3蛋白D2区域上的疏水残基介导同源二聚化，以及D2区域存在关键的糖基化，增强了D1-D2界面的接触面积和稳定性，进而正确定位D1区域以结合配体。近期利用冷冻电镜解析的人源LAG-3/favezelimab复合物进一步补充了这一结构模型：LAG-3的D3-D4区因高度柔性呈现为延伸、构象不稳定的“摆动”区段，表明D3-D4区可能提供较大的构象自由度，使D1-D2区能够在配体识别、二聚化或受体排列过程中实现必要的空间调整。而有研究发现，LAG-3的二聚体结构对于其在CD8+ T细胞上与TCR-CD3复合体的偶联至关重要，而缺乏二聚化能力的LAG-3突变体将无法有效抑制T细胞信号。这种通过D2二聚化来调控远端D1结合活性并介导近端TCR复合体相互作用的机制，构成了LAG-3抑制T细胞激活的独特分子基础。
1.2 LAG-3配体及其结合机制
1.2.1 MHCⅡ类分子-LAG-3轴介导的T细胞抑制机制
LAG-3的抑制功能是通过与其胞外区结合一系列跨膜或可溶性配体来实现的。MHCⅡ类分子是LAG-3发现后的首个被确认的配体。同CD4的结构同源性表明，LAG-3应具有结合MHCⅡ类分子的能力，这一构想随即通过细胞黏附实验得以验证。相比CD4，LAG-3的N端D1域存在一个额外的环状结构。随后的研究表明，LAG-3优先识别稳定的肽-MHCⅡ类分子复合物（peptide-MHCⅡ类分子complex, pMHCⅡ类分子），同时LAG-3和CD4并不竞争同一个MHCⅡ类分子结合位点，其通过其胞内结构域传递抑制信号来特异性抑制响应这些稳定抗原的CD4⁺ T细胞。通过结构解析发现，LAG-3通过其D1域以一个不同于CD4的结合界面与MHCⅡ类分子α链区域特异结合并且与CD4在MHCⅡ类分子的结合界面存在重叠，并明确了LAG-3二聚体通过其两个D1域同时结合两个MHCⅡ类分子。而进一步解析结构表明，LAG-3和CD4不能同时与MHCⅡ类分子结合，通过一系列实验和靶向MHCⅡ类分子的特异性抗体44H10，已经证明LAG-3介导的CD4-MHCⅡ类分子相互作用的阻断。根据LAG3-MHCⅡ类分子相互作用（KD ≈ 5~50 μmol/L）以及CD4-MHCⅡ类分子相互作用（KD > 200 μmol/L），这一结论表明LAG-3似乎不可避免地会与CD4竞争结合MHCⅡ类分子。综上所述，在生理激活的情况下，LAG-3是否可以和CD4与MHCⅡ类分子的竞争仍需要进一步实验来验证。
除CD4⁺ T细胞外，LAG-3还可抑制CD8⁺ T细胞的活化,在重组激活基因全敲小鼠中，CD8⁺ T细胞数量显著升高并表现出自发活化特征。同时另一研究指出，缺失MHCⅡ类分子的CD8⁺ T细胞在淋巴减少环境中发生显著的过度增殖。而在同源MHCⅠ类分子存在的情况下，MHCⅡ类分子对LAG-3⁺ CD8⁺ T细胞反应仅表现出有限的抑制作用，相比之下，同源MHCⅡ类分子对CD4⁺ T细胞反应所施加的抑制则更为强烈。近期研究表明，LAG-3在不依赖MHCⅡ类分子的情况下与TCR-CD3复合物物理接触，并阻断CD4/CD8向TCR递送LCK，从而降低CD3ζ链磷酸化并抑制T细胞活化。特异性靶向LAG-3 D2域的小鼠单克隆抗体C9B7W可破坏LAG-3的同源二聚体结构，并降低其在TCR复合物中的定位。目前，尚未探清LAG-3中介导与TCR-CD3复合体相互作用的结构域和残基。这一发现解释了LAG-3与PD-1/CTLA-4的功能差异，并表明pMHCⅡ类分子-LAG-3结合可能在LAG-3表达量受限的T细胞中放大其抑制效应，构成顺式信号调控与配体依赖增强的双层机制，并对今后靶向LAG-3的免疫治疗策略具有重要意义。
1.2.2 FGL1-LAG-3轴介导的T细胞抑制机制
FGL1是近年来发现的LAG-3配体，主要由肝细胞分泌，在多种肿瘤细胞中也高表达。FGL1是同源二聚体蛋白，正常情况下在血浆中维持较高浓度，参与肝再生和急性期反应。2019年，FGL1被鉴定为LAG-3的主要非MHCⅡ类分子类配体，研究显示，FGL1能以较高亲和力结合LAG-3，并显著抑制T细胞增殖与效应功能，同时在多种实体瘤中异常高表达，阻断FGL1-LAG-3相互作用可恢复T细胞活性并增强抗PD-1治疗效果。FGL1蛋白包含一个介导寡聚化的卷曲-卷曲结构域（coil-coil domain, CCD）以及一个纤维蛋白原样结构域（fibrinogen-like domain, FD）。通过结构研究发现，C9B7W的抗肿瘤活性主要依赖于其在LAG-3结合MHCⅡ类分子或FGL1后干扰其同源二聚体结构，从而阻断抑制性信号。而在F-盒蛋白38（F-box protein 38, FBXO38）-FGL1轴的研究表明，FBXO38通过介导FGL1的泛素化降解来调控其稳定性，而对肿瘤细胞中FBXO38的缺失会导致FGL1异常积累，从而增强其介导的免疫抑制作用。结合高维组织成像所揭示的FGL1⁺肿瘤细胞与CD8⁺ TIL的空间共定位，这些证据共同支持FGL1在肿瘤微环境中显著促进免疫抑制。最新研究发现，膜结合型FGL1能够触发LAG-3的K490位点泛素化，而可溶性FGL1则不能，这提示FGL1可能需要在细胞膜上聚集或与其他分子（如MHCⅡ类分子）协同才能有效激活LAG-3的抑制功能；此外，FGL1触发LAG-3泛素化的过程需要MHCⅡ类分子阻断解除，暗示FGL1可能通过改变LAG-3构象来促进泛素化，而非直接招募卡西塔斯B淋巴瘤蛋白（Casitas B-Lymphoma, CBL)。
总之，目前认为MHCⅡ类分子和FGL1在不同生理和病理条件下可能发挥不同程度的作用：在生理性免疫应答中，MHCⅡ类分子是主要配体；而在肿瘤微环境中，特别是在肝癌等FGL1高表达的肿瘤中，FGL1可能发挥更重要的作用。
1.2.3 其他配体介导的T细胞抑制机制
半乳糖凝集素-3（galectin-3, Gal-3）、肝窦内皮细胞C型凝集素（liver and lymph node sinusoidal endothelial cell C-type lectin, LSECtin）、α-突触核蛋白（alpha-synuclein, α-syn） 同样被鉴定为LAG-3的潜在配体。然而，这些分子作为LAG-3潜在配体的分子机制尚未完全阐明。Gal-3被报道可通过与LAG-3协同抑制CD8⁺ T细胞功能，从而促进肿瘤免疫抑制。黑色素瘤细胞高表达的LSECtin可与CD8⁺ T细胞上的LAG-3结合，导致CD8⁺ T细胞IFN-γ分泌显著下降，使其功能被抑制。随后证实眼部肿瘤中LSECtin、Gal-3、人类白细胞抗原Ⅱ类分子（human leukocyte antigen class Ⅱ, HLA-Ⅱ）在肿瘤细胞和免疫细胞上也伴随LAG-3的高表达而显著上调。最新研究表明，肝窦内皮细胞上的LSECtin通过与CD4⁺ T细胞（主要是Th17亚群）表面的LAG-3结合，显著抑制Th17细胞在肝内的过度扩增和炎症因子分泌。α-syn曾被提出以高亲和力结合LAG-3并驱动帕金森病相关的α-syn病理播散；然而，后续研究验证得出LAG-3在人类及小鼠神经元中几乎不表达，且敲除LAG-3完全不影响α-syn病理传播与神经元丢失。最新研究证实,类淀粉前体样蛋白1（amyloid precursor-like protein 1, Aplp1）是LAG-3的关键辅助受体，两者形成复合物大幅增强α-syn预制前体纤维（α-syn preformed fibrils, α-syn PFF）在神经元间的结合、内吞和细胞间传播，同时在PD小鼠模型中，外周血α-syn PFF通过内皮LAG-3介导的内吞加剧脑内α-syn病理和神经退行。综合现有证据，LSECtin、Gal-3与α-syn PFF的作用机制缺乏充分的结构和功能验证，其具体机制及生理病理学意义有待进一步明确。图1归纳了主要免疫检查点受体及其配体。
LAG-3信号转导机制
LAG-3通过多种机制抑制T细胞的活化和效应功能，其信号转导通路的复杂性近年来逐渐被揭示。与传统免疫检查点分子（如PD-1、CTLA-4）不同，LAG-3的胞内区不含经典的ITIM或ITSM，而是通过独特的功能性基序介导抑制信号。
2.1 LAG-3的基底信号与配体诱导信号
LAG-3的信号转导与抑制功能可分为两种模式：基底信号（tonic signaling）和配体诱导的信号（ligand-induced signaling）。
基底信号产生的抑制是指LAG-3在未与配体结合时即对T细胞产生一定程度的抑制作用。这种抑制可能通过LAG-3与TCR-CD3复合物在T细胞表面处于同样的位置造成的。研究发现，即使在缺乏MHCⅡ类分子或其他已知配体的情况下，LAG-3缺失的T细胞仍表现出增强的活化和增殖能力，提示LAG-3具有配体非依赖性的内在抑制功能。这种持续性抑制可能通过LAG-3胞内区的基本抑制基序（如EP基序）调控T细胞的活化阈值。配体诱导的抑制则是LAG-3与配体（如MHCⅡ类分子、FGL1）结合后触发的更强、更特异的抑制信号。近年来的研究揭示，配体诱导的LAG-3功能依赖于关键的泛素化修饰事件。
2.2 LAG-3信号基序及其功能
LAG-3的胞内端包含系统发育上保守但功能尚未明确定义的关键基序，包括近膜端的BRS和FSALE基序（含有潜在的丝氨酸磷酸化位点），KIEELE基序（含有泛素化位点K490）以及C端重复的EP基序。早期研究通过酵母双杂交筛选得到LAG-3相关蛋白（LAG-3-associated protein, LAP）能特异性地结合LAG-3胞内区段中存在EP重复序列基序，但此项研究并未得到后续研究的进一步验证。
LAG-3信号转导的核心机制是配体诱导的K490位点K63连接多聚泛素化。此发现是LAG-3功能研究的重大突破。首先，泛素化作为LAG3信号的分子开关：在静息状态下，LAG-3的胞内区FSALE基序通过疏水作用嵌入细胞膜，处于“隐藏”状态，无法招募下游信号分子，通过对FSALE基序的突变实验证明了FSALE是LAG-3抑制功能的核心执行元件。当LAG-3与配体（MHCⅡ类分子或膜结合型FGL1）结合后，T细胞激活触发CBL家族E3泛素连接酶（主要是CBL-b和c-CBL）的磷酸化和招募。CBL介导LAG-3 K490位点的K63连接多聚泛素化，这种非降解性泛素化修饰导致FSALE基序从膜上释放进入胞质，暴露给下游抑制性信号分子。其次，LAG-3泛素化缺失的突变体（将K490突变为精氨酸）显著丧失抑制功能，在肿瘤模型中的表现与LAG-3完全敲除小鼠相似。这直接证明了泛素化对LAG-3抑制功能的必需性。同期研究表明，PD-1/LAG-3共信号重编程的T细胞和PD-1/PD-L1抗体治疗无反应的非小细胞肺癌(NSCLC)患者的T细胞中均观察到c-Cbl/Cbl-b的高表达和富集。FSALE基序释放后的具体下游效应分子仍在研究中，目前认为可能包括：（1）干扰LCK激酶的募集和活化（EP基序机制）；（2）破坏CD3ε-LCK液-液相分离凝聚体的形成，从而抑制TCR近端信号放大；（3）可能招募其他抑制性磷酸酶或衔接蛋白。
LAG-3胞内区的EP基序（Glu-Pro二肽重复序列）是其抑制功能的另一关键结构。实验证据显示，LAG-3缺失的T细胞在最适TCR刺激条件下表现出持续的钙离子内流、持续的ZAP70、AKT和ERK磷酸化，证实LAG-3在TCR近端信号节点发挥抑制作用。该效应取决于高度酸性的EP基序能够通过静电作用与CD4/CD8碱性的胞内端结合，并降低TCR-CD3-CD4/CD8复合物周围的局部pH，从而破坏共受体与LCK之间的相互作用。
综合当前研究（图2），LAG-3的信号转导可概括为以下模型。在静息状态（未与配体结合）时，LAG-3定位于TCR-CD3复合体附近，其EP基序维持基础抑制，设定T细胞活化阈值。在激活状态（配体结合）时，LAG-3与稳定pMHCⅡ类分子或膜结合型FGL1结合后，T细胞活化诱导CBL磷酸化并招募至LAG-3，介导K490位点K63泛素化。泛素化触发FSALE基序从膜上释放，激活LAG3下游信号。
在LAG-3胞外的D4区域和跨膜区之间存在一个连接肽（connecting peptide, CP），在CP区域LAG-3会被切割成两个片段，形成可溶性LAG-3（soluble LAG-3, sLAG-3）。后续研究发现，两种关键的金属蛋白酶ADAM10和ADAM17负责LAG-3在CP区域的剪切。在不能裂解的LAG-3突变体（non-cleavable LAG-3, LAG-3NC）T细胞中，其增殖和细胞因子产生(如IL-2、IFN-γ)显著低于野生型LAG-3 T细胞。而在转入LAG-3NC的小鼠中，PD-1阻断治疗表现出抵抗，并且不能产生有效的抗肿瘤免疫反应。同时在头颈部鳞状细胞癌患者的外周血中，CD4+ FOXP3- T细胞上的高LAG-3表达与低ADAM10表达呈负相关，与较差的预后有关。目前研究数据倾向于sLAG-3作为肿瘤和炎症相关疾病早期诊断或预后的生物标志物，而单体的sLAG-3的功能效应则需要进一步的研究。
LAG-3在多种淋巴系和非淋巴系细胞中广泛表达，并在肿瘤或慢性病毒感染导致的持续抗原刺激条件下，其表达是CD4⁺和CD8⁺ T细胞耗竭的标志；此外，LAG-3在调节性T细胞（Treg细胞）以及CD4⁺ Ⅰ型调节性T细胞（type 1 Treg细胞，Tr1细胞）和部分NK细胞、NKT细胞、B细胞和pDC上均有表达。然而，在非T细胞的研究中，LAG-3的功能尚未明确。早期研究指出，CD4⁺ CD25⁻ T细胞上LAG-3异位表达可以显著抑制它们的增殖，并赋予它们对效应T细胞的抑制能力。另一研究指出，IL-27信号能上调Treg细胞表面的LAG-3表达，并通过促进其抑制性分子及相关转录程序，显著增强Treg细胞的免疫抑制能力。近年研究发现，LAG-3通过抑制Myc依赖的代谢程序来维持Treg细胞的稳定性和抑制功能。在小鼠的脾脏和胸腺中，约10%的NK细胞表达LAG-3。单细胞转录组数据表明，这些细胞表现出与T细胞耗竭相似的状态与较低效应功能。体外或小鼠模型显示，用LAG-3-Fc或阻断性抗体可以在某些条件下恢复或增强NK细胞的IFN-γ产生和增殖指标。
基于LAG-3的免疫治疗
3.1 靶向LAG-3治疗策略
LAG-3作为抑制性受体，其在肿瘤、自身免疫性疾病、慢性病毒感染以及神经退行性疾病中都起到重要作用。在肿瘤微环境中，LAG-3以及其他抑制性受体[PD-1、T细胞免疫球蛋白和ITIM结构域蛋白（T cell immunoglobulin and ITIM domain protein, TIGIT）和细胞免疫球蛋白黏蛋白-3（T cell immunoglobulin mucin-3, TIM3）]的持续表达通常与T细胞耗竭表型一致。在TIL上，LAG-3的高表达抑制CD4+和CD8+ T细胞分泌生长因子。更多研究指出，TIL上LAG-3的高表达在多种癌症中与不良预后和无病生存期短有关。目前，LAG-3成为继PD-1和CTLA-4后的第3个获批临床应用的免疫检查点。在多项临床前研究中，LAG-3单一拮抗剂疗法展现的抗肿瘤效果有限，而与PD-1阻断剂联合应用时，实验小鼠模型中可观察到显著的肿瘤清除现象，并实现了生存期的显著延长。
3.2 LAG-3单克隆抗体
针对LAG-3的单克隆抗体是目前研发最为成熟的LAG-3靶向治疗药物。这些抗体通过阻断LAG-3与其配体的相互作用，解除对T细胞的抑制，恢复抗肿瘤免疫应答。目前，relatlimab是全球首个获批的抗LAG-3单克隆抗体。该抗体是百时美施贵宝公司开发的一种人IgG4抗体，其通过高亲和力结合LAG-3的胞外域，阻断其与MHCⅡ类分子和FGL1等配体的相互作用。该抗体已获美国FDA批准与nivolumab（抗PD-1抗体）联用治疗黑色素瘤患者。Relatlimab正在多种实体瘤中进行临床试验，包括NSCLC、肾细胞癌、头颈部鳞癌、胃癌等。
3.3 LAG-3激活抗体
近年来，抑制性免疫检查点受体的激动剂逐渐成为自身免疫性疾病治疗中备受关注的潜在药物策略。早期报道一种LAG-3激动型抗体——IMP761（由Immutep公司研发），其能显著抑制原代T细胞及多种T细胞系的增殖与活化；此外，IMP761的治疗潜力还在非人灵长类动物（食蟹猴）迟发型超敏反应模型中得到评估，IMP761治疗组中约50%的食蟹猴DTH相关红斑表现出完全缓解。近期研究提出了一种新型双特异T细胞抑制抗体（bispecific T cell silencer， BiTS）。该抗体同时结合LAG-3与TCR/CD3复合体，通过在同一T细胞膜上强制拉近二者的空间邻近性（cis-proximity），增强了LAG-3对TCR信号的抑制作用。与单纯依赖配体结合不同，BiTS利用LAG-3的内在抑制能力，促进TCR早期信号分子（如LCK）从受体复合体中解离，从而显著提高T细胞激活阈值。
3.4 LAG-3治疗相关的生物标志物
识别能够预测LAG-3靶向治疗疗效的生物标志物对于患者筛选、疗效监测和克服耐药至关重要。目前研究的生物标志物包括sLAG-3、LAG-3的表达模式及新兴的LAG-3泛素化标志物。
sLAG-3是LAG-3胞外域被金属蛋白酶ADAM10和ADAM17切割释放到血清和其他体液中的形式。多种肿瘤患者血清sLAG-3水平升高，包括肾细胞癌、黑色素瘤、淋巴瘤等。高sLAG-3水平与肿瘤负荷、疾病进展和不良预后相关。sLAG-3可能反映TIL的激活状态和耗竭程度。同时，系统性红斑狼疮、类风湿关节炎、慢性病毒感染等患者sLAG-3水平升高。部分研究显示，免疫治疗后sLAG-3水平变化可能预测疗效，但结论尚不一致。
LAG-3蛋白在TIL上的表达模式也可以作为生物标志物。在多种实体瘤中，20%~60%的CD8⁺ TIL表达LAG-3。三重阳性（LAG-3⁺/PD-1⁺/TIM-3⁺）TIL比例与更严重耗竭相关。在PD-1/PD-L1单药治疗中，LAG-3⁺ TIL比例高的患者对PD-1单药应答率可能较低，因此，高LAG-3表达可能是PD-1单药耐药的机制之一。在LAG-3 + PD-1双阻断治疗中，理论上LAG-3⁺/PD-1⁺双阳性TIL比例高的患者更可能从双阻断中获益，这个设想需要进一步验证。
展 望
LAG-3作为第三个成功进入临床应用的免疫检查点靶点，为肿瘤免疫治疗开辟新的途径。Opdualag（relatlimab + nivolumab固定剂量组合，百时美施贵宝公司）的获批标志着LAG-3 + PD-1双阻断策略的成功，为更多患者提供了治疗选择。然而，LAG-3的生物学复杂性、与其他检查点的协同作用机制、最佳生物标志物的识别等问题仍需深入研究。
未来，随着对LAG-3信号转导机制（特别是泛素化调控、配体选择性等）的深入理解，以及高通量组学分析技术和人工智能在生物标志物开发中的应用，LAG-3靶向治疗有望实现更精准的患者分层和个体化治疗方案制定。创新的联合治疗策略、新型LAG-3靶向药物以及在其他疾病领域的探索，将进一步拓展LAG-3的临床应用价值。
引用本文
任骁华,王皞鹏.免疫检查点LAG-3的功能机制与临床应用. [J].中国肿瘤生物治疗杂志, 2025, 32(12): 1211-1220. DOI：10.3872/j.issn.1007-385x.2025.12.001
图文：苏 念
一审：黄静怡
二审：于益芝
三审：曹雪涛
2025-12-31
·肤界
2025年，国际皮肤科领域持续快速发展。越来越多来自中国的研究者，出现在 British Journal of Dermatology（BJD）、Journal of the American Academy of Dermatology（JAAD）、JAMA Dermatology、
Journal of the European Academy Of Dermatology and Venereology（JEADV）、Journal Investigative of Dermatology（JID）、Nature、Cell等国际权威期刊的作者名单中。这些论文是中国皮肤科在全球学术舞台上持续发声、深入对话的成果。
延续上篇盘点，肤界编辑部继续整理2025年度来自中国作者的研究成果，涵盖皮肤科不同方向与创新前沿。这份盘点记录了中国皮肤科的年度精彩成果，每一篇上榜论文，都是2025年中国皮肤科研路上的闪亮印记。
这是你2025年的一部分
也是中国皮肤科这一年共同完成的一次亮相
这一页，值得被留在2025年末的朋友圈里
2025年度JAMA Dermatology合集列表
（最新IF：11.0）
1.经皮耳迷走神经刺激治疗红斑毛细血管扩张性玫瑰痤疮：一项随机临床试验
Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Erythematotelangiectatic Rosacea: A Randomized Clinical Trial
Jian Li 1, Jinyu Wei 2, Mingwang Zhang, Minmin Kong, Lijuan Xie, Mei Wan, Zhifei Pan, Jing Tian, Zuzhen Ou, Shuguang Chen, Aiai Xia, Li Tang, Zhiqiang Song, Jingming Hou, Fei Hao
JAMA Dermatol. 2025 Dec 1;161(12):1229-1237.
PMID: 41060641
PMCID: PMC12509084 (available on 2026-10-08)
DOI: 10.1001/jamadermatol.2025.3796
2.伊马替尼治疗胃肠道间质瘤期间广泛性瘢痕疙瘩的消退
Regression of Extensive Keloids During Imatinib Therapy for Gastrointestinal Stromal Tumor
Yi-Han Chang 1, John A McGrath 1, Chao-Kai Hsu
JAMA Dermatol. 2025 Dec 1;161(12):1293-1294.
PMID: 41191377 DOI: 10.1001/jamadermatol.2025.4072
3.颈部环形皮肤病变
Annular Cutaneous Lesion of the Neck
Yi-Xiao Wang 1, Min Gao 1, Li-Xiong Gu
JAMA Dermatol. 2025 Nov 1;161(11):1177-1178.
PMID: 40991266 DOI: 10.1001/jamadermatol.2025.2592
4.乌帕替尼治疗汗孔角化症
Treatment of Porokeratosis Ptychotropica With Upadacitinib
Shuai Zhang, Lu Bian, Meng-Yao Zhang, Jin-Fa Dou, Hong-Wei Liu, Jian-Guo Li, Jian-Bo Wang
JAMA Dermatol. 2025 Nov 1;161(11):1191-1193.
PMID: 41032324 DOI: 10.1001/jamadermatol.2025.3519
5.银屑病治疗中的生物制剂转换：系统评价与荟萃分析
Biopharmaceutical Switching in Psoriasis Treatment: A Systematic Review and Meta-Analysis
Miao Zhang, Seokgyeong Hong, Qingyun Wang, Xiaoying Sun, Yaqiong Zhou, Ying Luo, Liu Liu , Jiao Wang, Chunxiao Wang, Naixuan Lin, Juntang Yan, Xin Li
JAMA Dermatol. 2025 Aug 6;161(10):1029-1038.
PMID: 40768223
PMCID: PMC12329682 (available on 2026-08-06)
DOI: 10.1001/jamadermatol.2025.2714
6.2-光子显微镜对黄褐斑病理特征及治疗反应的体内评估
In Vivo Evaluation of Melasma Pathologic Features and Treatment Response by 2-Photon Microscopy
Xiaoli Ning, Jungang Yang, Hongfei Ouyang, Lingfan Jiang, Ruixing Yu, Chengxu Li, Yujun Sheng, Xuejiao Song, Jingkai Xu, Xianbo Zuo, Yong Cui
JAMA Dermatol. 2025 Aug 13;161(10):1039-1047.
PMID: 40802269
PMCID: PMC12351471 (available on 2026-08-13)
DOI: 10.1001/jamadermatol.2025.2790
7.用于皮肤海分支杆菌感染病因学诊断的靶向新一代测序
Targeted Next-Generation Sequencing for Etiologic Diagnosis of Cutaneous Mycobacterium marinum Infection
An-Kang Gu, Wen-Hua Qin, Xiu-Jun Zhang, Fa-Ku Ma, Li-Tao Zhang
JAMA Dermatol. 2025 Aug 20;161(10):1086-1087.
PMID: 40833738
PMCID: PMC12368782 (available on 2026-08-20)
DOI: 10.1001/jamadermatol.2025.2905
8.增生性扁平苔藓
Hypertrophic Lichen Planus
Ruimiao Wu, Yu Hu
JAMA Dermatol. 2025 Sep 3.
PMID: 40900583 DOI: 10.1001/jamadermatol.2025.2995
9.埃万妥单抗诱导的头皮及面部坏死局部β阻滞剂湿敷疗法
Topical β-Blocker Wet Wrap Therapy for Amivantamab-Induced Scalp and Facial Necrosis
Hsuan-Chi Chen, Wen-Hung Chung 1, How-Wen Ko 2, Jong-Hwei Su Pang 4, Yu-Shien Ko, Mei-Jun Chen, Chun-Wei Lu
JAMA Dermatol. 2025 Sep 10.
PMID: 40928786 DOI: 10.1001/jamadermatol.2025.3122
10.寻常型狼疮
Lupus Vulgaris
Chuan-Peng Wang, Jia Zhou, Jun Li
JAMA Dermatol. 2025 Sep 1;161(9):970-971.
PMID: 40668574 DOI: 10.1001/jamadermatol.2025.1799
11.伴淋巴管炎的先天性耳聋
Orf With Lymphangitis
Yi-Shan Teng, Ting-Ting Yang
JAMA Dermatol. 2025 Sep 1;161(9):972-973.
PMID: 40768138 DOI: 10.1001/jamadermatol.2025.2400
12.乌帕替尼用于治疗高IgE综合征
Upadacitinib for Treatment of Hyper-IgE Syndrome
Qing Zhao 1, Yanhong Sun 1, Yonghu Sun 1, Hong Liu 1, Furen Zhang
JAMA Dermatol. 2025 Sep 1;161(9):984-985.
PMID: 40768139 DOI: 10.1001/jamadermatol.2025.2699
13.林普利塞联合西达本胺在复发或难治性皮肤T细胞淋巴瘤中的应用：一项非随机临床试验
Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma: A Nonrandomized Clinical Trial
Zhiyu Pang, Yupeng Wang 2, Zhaorui Liu, Shan Zhang, Chong Wei, Zhuofan Xu, Ziqian Wang, Hongyun Chen, Jie Liu, Wei Zhang
JAMA Dermatol. 2025 Sep 1;161(9):923-930.
PMID: 40601335
PMCID: PMC12224036 (available on 2026-07-02)
DOI: 10.1001/jamadermatol.2025.1926
14.接受度普利尤单抗治疗的特应性皮炎患者中的银屑病风险
Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab
Teng-Li Lin 1, Yi-Hsuan Fan, Kuo-Sheng Fan, Chao-Kuei Juan, Yi-Ju Chen, Chun-Ying Wu
JAMA Dermatol. 2025 Aug 1;161(8):813-821.
PMID: 40531497
PMCID: PMC12177727 (available on 2026-06-18)
DOI: 10.1001/jamadermatol.2025.1578
15.癌症患者抗肿瘤治疗后的自身免疫性皮肤病与生存结局
Autoimmune Skin Diseases and Survival Outcomes After Antineoplastic Treatment in Patients With Cancer
Sheng-Yin To 1, Cho-Hao Lee, Yi-Hsien Chen 6, Li-Fan Hsu, I-Wen Chen 3, Hui-Wen Yang, Yuan-Liang Wen, Li-Ting Kao
JAMA Dermatol. 2025 Aug 1;161(8):840-848.
PMID: 40601336
PMCID: PMC12224047 (available on 2026-07-02)
DOI: 10.1001/jamadermatol.2025.1949
16.下肢无症状对称性毛细血管扩张症
Asymptomatic Symmetrical Telangiectasia on Lower Extremities
Pei-Yun Ho, Yi-Tsz Lin
JAMA Dermatol. 2025 Aug 1;161(8):874-875.
PMID: 40531494 DOI: 10.1001/jamadermatol.2025.1416
17.儿童嗜酸性粒细胞增多伴全身症状的药物反应
Drug Reaction With Eosinophilia and Systemic Symptoms in Children
Lei Jiao, Yang Wang, Jing Tian, Mutong Zhao, Zigang Xu, Lin Ma, Yuan Liang
JAMA Dermatol. 2025 Aug 1;161(8):881-883.
PMID: 40531516
PMCID: PMC12177722 (available on 2026-06-18)
DOI: 10.1001/jamadermatol.2025.1651
18.与绑蟹相关的孢子丝菌病暴发
An Outbreak of Sporotrichosis Associated With Tying Crabs
Fangfang Bao, Pengcheng Huai, Chenchen Chen, Shufen Wang, Yong Zhang, Zige Li, Yongxia Liu, Gongqi Yu, Wenyan Ma, Meichen Han, Wenchang Zhao, Hong Liu 1, Furen Zhang
JAMA Dermatol. 2025 Aug 1;161(8):883-885.
PMID: 40601347
PMCID: PMC12224045 (available on 2026-07-02)
DOI: 10.1001/jamadermatol.2025.1884
19.司库奇尤单抗与乌帕替尼治疗Papillon-Lefèvre综合征2例报告
Secukinumab and Upadacitinib Treatment for Papillon-Lefèvre Syndrome in 2 Cases
Jiaying Li 1, Zhaoyang Wang 1, Zigang Xu
JAMA Dermatol. 2025 Aug 1;161(8):887-890.
PMID: 40632515 DOI: 10.1001/jamadermatol.2025.1639
20.1990年至2021年老年人皮肤癌负担及2050年模型预测
Burden of Skin Cancer in Older Adults From 1990 to 2021 and Modelled Projection to 2050
Ruiyao Wang, Yangmei Chen, Xinyi Shao, Tingqiao Chen, Judan Zhong, Yi Ou, Jin Chen
JAMA Dermatol. 2025 Jul 1;161(7):715-722.
PMID: 40397469
PMCID: PMC12096324
DOI: 10.1001/jamadermatol.2025.1276
21.Hutchinson-Gilford早衰综合征
Hutchinson-Gilford Progeria Syndrome
Yu-Ting Tsai, Yi-Chien Yang
JAMA Dermatol. 2025 Jul 1;161(7):755-756.
PMID: 40366683 DOI: 10.1001/jamadermatol.2025.0793
22.艾玛昔替尼治疗成人及青少年中重度特应性皮炎：一项3期随机临床试验
Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial
Yan Zhao, Melinda Gooderham, Bin Yang, Jiyuan Wu, Liming Wu, Wei Jing Loo, Darryl Toth, Maxwell Sauder, Jingyi Li, Aijun Chen, Xiaohua Tao, Jianyun Lu, Zhiqiang Song, Jiande Han, Hongyi Li, Yijing Li, Lihong Xu, Jianzhong Zhang
JAMA Dermatol. 2025 Jul 1;161(7):688-697.
PMID: 40305055
PMCID: PMC12044538 (available on 2026-04-30)
DOI: 10.1001/jamadermatol.2025.0982
23.外阴和大腿上的丘疹性及水疱性皮损
Papular and Vesicular Lesions on the Vulva and Thighs
Teng Liu, Jianmin Chang
JAMA Dermatol. 2025 Jul 1;161(7):761-762.
PMID: 40465257 DOI: 10.1001/jamadermatol.2025.1407
24.具有新型MGP变异的弹性假黄瘤样表型
Pseudoxanthoma Elasticum-Like Phenotype With a Novel MGP Variant
Yun-Shiuan Olivia Hsu, Rai-Hseng Hsu, Jau-Yu Liau, Ni-Chung Lee, Yin-Hsiu Chien, Yi-Hua Liao
JAMA Dermatol. 2025 Jul 1;161(7):773-775.
PMID: 40397434 DOI: 10.1001/jamadermatol.2025.1019
25.TRPM4基因合子后获得性功能增强变异与炎症性线状疣状表皮痣
Postzygotic Gain-of-Function Variant in TRPM4 and Inflammatory Linear Verrucous Epidermal Nevus
Zhouliang Liu, Zhijun Zhao, Kunlun Lv, Huijun Wang, Fan Yang, Zhimiao Lin
JAMA Dermatol. 2025 Jul 23.
PMID: 40699612 DOI: 10.1001/jamadermatol.2025.2205
26.阿布昔替尼治疗滑膜炎、痤疮、脓疱病、增生症及骨炎综合征
Treatment of Synovitis, Acne, Pustulosis, Hyperstosis, and Osteitis Syndrome With Abrocitinib
Dawei Huang 1, Yujing Zhao 2, Yuling Shi 1, Xuemei Yi
JAMA Dermatol. 2025 Jun 1;161(6):668-669.
PMID: 40332901 DOI: 10.1001/jamadermatol.2025.1010
27.前胸孤立性红斑
An Isolated Red Plaque on the Anterior Chest
Bin Peng, Xiaojuan Nan, Songmei Geng
JAMA Dermatol. 2025 Jun 1;161(6):652-653.
PMID: 40305037 DOI: 10.1001/jamadermatol.2025.0745
28.单纯光动力疗法与抗生素联合治疗皮肤马立克氏菌感染
Cutaneous Mycobacterium marinum Treated With Photodynamic Therapy Alone and Combined With Antibiotics
Wenlong Hu, Qiunan Yao, Yue Mou, Chaochao Ji, Wenhao Cheng, Renqiong Chen, Jiaqi Liu, Xudong Mou, Di Cao, Hong Ren
JAMA Dermatol. 2025 Jun 1;161(6):663-666.
PMID: 40266582
PMCID: PMC12019672 (available on 2026-04-23)
DOI: 10.1001/jamadermatol.2025.0645
29.脱毛性毛囊炎
Folliculitis Decalvans
Lijuan Zhou, Jinran Lin, Wenyu Wu
JAMA Dermatol. 2025 May 1;161(5):544-545.
PMID: 40105835 DOI: 10.1001/jamadermatol.2025.0050
30.妊娠期化脓性汗腺炎用药影响的再评估
Reexamining Medication Impact in Hidradenitis Suppurativa and Pregnancy
Yan-Han Li, Shu-Han Chuang, Hui-Ju Yang
JAMA Dermatol. 2025 May 1;161(5):561.
PMID: 40202763 DOI: 10.1001/jamadermatol.2025.0507
31.甲下无色素性黑色素瘤
Subungual Amelanotic Melanoma
Xing Fang, Tianjing Gao, Yu Fu
JAMA Dermatol. 2025 Apr 1;161(4):432-433.
PMID: 40042859 DOI: 10.1001/jamadermatol.2024.6167
32.发热性溃疡坏死性Mucha-Habermann病
Febrile Ulceronecrotic Mucha-Habermann Disease
Yi-Hsuan Shen, Yu-Ting Hung
JAMA Dermatol. 2025 Apr 1;161(4):430-431.
PMID: 39969860 DOI: 10.1001/jamadermatol.2024.6162
33. Stevens-Johnson综合征/中毒性表皮坏死松解症幸存者心血管疾病发病率与死亡率风险
Risk of Cardiovascular Morbidity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Survivors
Hsien-Yi Chiu, Ying-Ming Chiu
JAMA Dermatol. 2025 Apr 1;161(4):391-398.
PMID: 39969876
PMCID: PMC11840681 (available on 2026-02-19)
DOI: 10.1001/jamadermatol.2024.5881
34.胸部圆形坏死性黄红色斑块
Circular Necrotic Yellow-Red Plaque on the Chest
Tian-Yi Zhang 1, Yue-Ping Zeng
JAMA Dermatol. 2025 Apr 1;161(4):434-435.
PMID: 40042862 DOI: 10.1001/jamadermatol.2025.0028
35.贫血痣
Nevus Anemicus
Xuemei Lan, Xiaopo Wang
JAMA Dermatol. 2025 Mar 1;161(3):322-323.
PMID: 39937468 DOI: 10.1001/jamadermatol.2024.6031
36.抗IL-23单克隆抗体QX004N治疗银屑病的安全性与有效性：一项随机临床试验
Safety and Efficacy of Anti-IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis: A Randomized Clinical Trial
Xiaojiao Li, Bing Li, Deming Yang, Meng Wang, Qianqian Li, Nan Wang, Min Fang, Jingrui Liu, Hong Zhang, Min Wu, Cuiyun Li, Xiaoxue Zhu, Yanhua Ding, Shanshan Li
JAMA Dermatol. 2025 Mar 1;161(3):247-255.
PMID: 39661362
PMCID: PMC11840649
DOI: 10.1001/jamadermatol.2024.5059
37.年轻女性肉芽肿性唇炎
Granulomatous Cheilitis in a Young Woman
Zheng Su, Si-Jia Zhao, Yue-Ping Zeng
JAMA Dermatol. 2025 Feb 1;161(2):210-211.
PMID: 39745741 DOI: 10.1001/jamadermatol.2024.5502
38.免疫检查点抑制剂与银屑病风险
Psoriasis Risk With Immune Checkpoint Inhibitors
Sheng-Yin To, Cho-Hao Lee, Yi-Hsien Chen, Chia-Lu Hsu, Hui-Wen Yang, Ying-Shan Jiang, Yuan-Liang Wen, I-Wen Chen 3, Li-Ting Kao
JAMA Dermatol. 2025 Jan 1;161(1):31-38.
PMID: 39504056
PMCID: PMC11541743
DOI: 10.1001/jamadermatol.2024.4129
39.手掌筋膜炎和多关节炎综合征
Palmar Fasciitis and Polyarthritis Syndrome
Xiao Ma, Dong-Lai Ma
JAMA Dermatol. 2025 Jan 1;161(1):98-99.
PMID: 39630476 DOI: 10.1001/jamadermatol.2024.5015
40.佩索利单抗在糖皮质激素抵抗性Sweet综合征患者中的疗效
Spesolimab Response in a Patient With Steroid-Resistant Sweet Syndrome
Zhiyu Pang, Chao Wu, Jie Liu, Yuehua Liu, Hongzhong Jin
JAMA Dermatol. 2025 Jan 1;161(1):110-112.
PMID: 39535809 DOI: 10.1001/jamadermatol.2024.4342
2025年度JEADV合集列表
（最新IF：8.0）
1.利特昔替尼治疗斑秃的真实世界疗效与安全性：单中心经验
Real-world efficacy and safety of ritlecitinib in alopecia areata: A single-centre experience
Youyu Sheng , Qin Wang , Ke Tao , Kai Yang , Yifei Zhu , Zheng Li , Chunya Ni , Jinran Lin , Wenyu Wu
J Eur Acad Dermatol Venereol. 2025 Dec;39(12):e996-e998.
PMID: 40130934 DOI: 10.1111/jdv.20664
2.对Preuß 等人‘度普利尤单抗：倾向性匹配队列中未发现母体风险升高’的回应
Response to 'Dupilumab: No elevated maternal risks in propensity-matched cohort' by Preuß et al
Yan Teng , Qiong Gao , Jie Chen , Xiaohua Tao
J Eur Acad Dermatol Venereol. 2025 Dec;39(12):e1079-e1080.
PMID: 40616363 DOI: 10.1111/jdv.20819
3.度普利尤单抗降低特应性皮炎感染风险的获益尚未得到充分认识
Underrecognized infection-reducing benefits of dupilumab in atopic dermatitis
Shiuan-Chih Chen, Yuan-Ti Lee
J Eur Acad Dermatol Venereol. 2025 Dec;39(12):e1063-e1064.
PMID: 40536414 DOI: 10.1111/jdv.20805
4.AI生成皮肤科图像中的隐藏模式与被忽视的陷阱：超越表面多样性
Hidden patterns and overlooked pitfalls in AI-generated dermatology images: Beyond surface diversity
Chao-Bin Yeh , Shiuan-Chih Chen
J Eur Acad Dermatol Venereol. 2025 Dec;39(12):e1065-e1066.
PMID: 40785165 DOI: 10.1111/jdv.70002
5.以急性乳腺炎为首发表现的二期梅毒
Secondary syphilis with acute mastitis as the initial manifestation
Ming-Ming Zhou, Long Geng
J Eur Acad Dermatol Venereol. 2025 Dec;39(12):2142.
PMID: 40052240 DOI: 10.1111/jdv.20592
6.婴儿血管瘤对普萘洛尔治疗反应不佳的危险因素：一项前瞻性研究
Risk factors for a poor response to propranolol for infantile haemangioma: A prospective study
Kaizhi Zhang , Tong Qiu , Xue Gong , Jiangyuan Zhou , Yuru Lan , Zixin Zhang , Yi Ji
J Eur Acad Dermatol Venereol. 2025 Dec;39(12):e1039-e1041.
PMID: 40624963 DOI: 10.1111/jdv.20840
7.瘢痕疙瘩与增生性瘢痕病灶内治疗的疼痛模式：一项多中心观察性研究
Pain patterns in intralesional therapy for keloids and hypertrophic scars: A multicenter observational study
Yunyi Liu, Zixi Jiang, Dan Sun, Liang Zhang, Renliang He, Shuang Zhao
J Eur Acad Dermatol Venereol. 2025 Nov;39(11):e979-e982.
PMID: 40459278 DOI: 10.1111/jdv.20758
8.用于手术台针具管理的粘性磁性托盘
An adhesive magnetic tray for on-surgical-table needle management
Guoqun Yu , Fan Yang , Liu Yang , Yamin Zhang , Juan Tao
J Eur Acad Dermatol Venereol. 2025 Nov;39(11):e977-e978.
PMID: 40365773 DOI: 10.1111/jdv.20749
9.高频超声检查联合Mohs显微手术治疗复发性 DFSP
High-frequency ultrasonography combined with Mohs micrographic surgery for treating recurrent DFSP
Yuancheng Liu, Shuang Zhao, Tianhong Wei
J Eur Acad Dermatol Venereol. 2025 Nov;39(11):e983-e986.
PMID: 40298455 DOI: 10.1111/jdv.20722
10.平衡疗效与患者体验：模拟日光PDT治疗浅表BCC的审慎视角
Balancing efficacy and patients experience: A cautious perspective on simulated daylight PDT for superficial BCC
Davis Yung Chan , Raphael Chan
J Eur Acad Dermatol Venereol. 2025 Nov;39(11):1876-1877.
PMID: 41137684 DOI: 10.1111/jdv.70018
11.牧民Orf病毒感染：一种模拟猴痘病毒（Mpox）及其他皮肤病变的人畜共患病毒
Orf virus infection in a herder: A zoonotic poxvirus mimicking Mpox and other cutaneous lesions
Xu Li, Qiri Mu
J Eur Acad Dermatol Venereol. 2025 Nov;39(11):2005.
PMID: 40231386 DOI: 10.1111/jdv.20695
12.JAK抑制剂治疗扁平苔藓性脱发或额部纤维性脱发的疗效与安全性
Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
Chaofan Wang , Yiqun Jiang
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):e882-e885.
PMID: 39995396 DOI: 10.1111/jdv.20614
13.全身性神经激肽-1受体拮抗剂缓解慢性瘙痒：系统评价与荟萃分析
Systemic neurokinin-1 receptor antagonists mitigate chronic pruritus: A systematic review and meta-analysis
Pei-Yun Ho , Yu-Chen Huang, Yi-Tsz Lin
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):1738-1749.
PMID: 40551532 DOI: 10.1111/jdv.20807
14.口服乌帕替尼联合窄谱中波紫外线治疗难治性进展性白癜风的病例系列研究
Treatment of refractory progressive vitiligo with oral upadacitinib and narrow-band ultraviolet-B: A case series
Zhenhua Yue, Xiaoxiao Yan, Yonghu Sun
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):e854-e856.
PMID: 39902936 DOI: 10.1111/jdv.20565
15.紫外线诱导荧光皮肤镜在斑秃毛囊开口检测中的应用
Ultraviolet-induced fluorescence dermoscopy in detecting follicular openings in alopecia areata
Xiaofan Jin , Wen Xu , Yujie Li , Xiuzu Song
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):e860-e861.
PMID: 39898616 DOI: 10.1111/jdv.20576
16.时机、年龄与免疫特征分析优化地衣样慢性移植物抗宿主病治疗策略
Timing, age and immune profiling refine strategy in lichenoid chronic graft-versus-host disease
Shiuan-Chih Chen, Tsai Ling Ting
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):e934-e935.
PMID: 40600498 DOI: 10.1111/jdv.20823
17.对Kakpovbia关于轻中度痤疮局部治疗有效性的文章评论
Comment on the article by Kakpovbia about efficacy of topical treatments for mild-to-moderate acne
Qing Long , Yan Li
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):e940-e941.
PMID: 40536411 DOI: 10.1111/jdv.20800
18.对Kogler关于生殖道外性传播感染流行率文章的评论
Comment on the article by Kogler about prevalence of extragenital sexually transmitted infections
Yan Li , Qing Long
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):e942-e943.
PMID: 40552892 DOI: 10.1111/jdv.20804
19.评估异维A酸妊娠预防依从性时未解决的混杂因素：呼吁进行更精细的分析
Unaddressed confounders in the evaluation of isotretinoin pregnancy prevention compliance: A call for refined analyses
Jianjun Hao , Dongmei Li , Jing Yang
J Eur Acad Dermatol Venereol. 2025 Oct;39(10):e936-e937.
PMID: 40298538 DOI: 10.1111/jdv.20710
20.生物制剂对银屑病患者焦虑抑郁症状的比较效应
Comparative effects of biologics on anxiety and depression symptoms in psoriasis
Yuxiong Jiang, Yu Wang, Dawei Huang, Min Dai, Xiaoyuan Zhong, Lingling Yao, Shuang Xu, Ying Li, Jiajing Lu, Yuling Shi
J Eur Acad Dermatol Venereol. 2025 Sep;39(9):e812-e815.
PMID: 40272021 DOI: 10.1111/jdv.20702
21.既往生物制剂暴露对特应性皮炎药物存活率的影响
Impact of prior biologic exposure on drug survival in atopic dermatitis
Xu Li, Shuang Wu , Yanfei Li, Jingxue Guo , Peng Jin , Lili Zhi
J Eur Acad Dermatol Venereol. 2025 Sep;39(9):e828-e829.
PMID: 40156232 DOI: 10.1111/jdv.20678
22.颗粒状角化不良
Granular parakeratosis
Shihui Zhou, Yifeng Guo
J Eur Acad Dermatol Venereol. 2025 Aug;39(8):1510.
PMID: 39912547 DOI: 10.1111/jdv.20574
23.结节性痒疹患者恶性肿瘤风险：系统评价与荟萃分析
Risk of malignancy in patients with prurigo nodularis: A systematic review and meta-analysis
Po-Yen Chang , Hsien-Yi Chiu
J Eur Acad Dermatol Venereol. 2025 Aug;39(8):e716-e719.
PMID: 39817665 DOI: 10.1111/jdv.20531
24.基于网络预测方法鉴定肢端黑色素瘤中两种分子及预后特征不同的亚型
Identification of two molecularly and prognostically distinct subtypes in acral melanoma using network prediction method
Mingzhu Yin, Yiding Zhang , Wenhua Wang , Shuang Zhao , Juan Su , Shao Li , Xiang Chen
J Eur Acad Dermatol Venereol. 2025 Jul;39(7):1254-1266.
PMID: 39282977
PMCID: PMC12188512
DOI: 10.1111/jdv.20335
25.大疱性类天疱疮患者功能衰退的探讨
Probing into functional decline among bullous pemphigoid patients
Wei-Zhen Tang , Kang-Jin Huang , Tai-Hang Liu
PMID: 39625222 DOI: 10.1111/jdv.20469
26.关于‘超越记分牌：教练对户外运动中紫外线相关皮肤癌的认知’的评论
Comment on 'Beyond the scoreboard: Coaches' UV-related skin cancer knowledge in outdoor sports'
Luo-Wei Chan , Shih-Hao Huang , Jian-Chih Chen, Chia-Hao Hsu
J Eur Acad Dermatol Venereol. 2025 Jul;39(7):e642-e643.
PMID: 39912336 DOI: 10.1111/jdv.20567
27.IL-24与大疱性类天疱疮严重程度的关联：一项病例对照研究
IL-24 for bullous pemphigoid severity: A case-control study
Yutong Ran , Xueting Peng , Yumin Xia , Yale Liu
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):e511-e513.
PMID: 39648873 DOI: 10.1111/jdv.20467
28.佩索利单抗治疗难治性儿童Hallopeau肢端皮炎连续病例系列报告
Spesolimab in refractory paediatric acrodermatitis continua of Hallopeau, a case series
Liting Cai , Yunling Yan , Yang Li , Junjie Lin , Xinyan She , Xiaohua Wang
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):e526-e528.
PMID: 39679631 DOI: 10.1111/jdv.20500
29.银屑病患者与医师对疾病活动度评估的差异：言语登记研究
Disagreement between physicians' and patients' assessment of disease activity in psoriasis: The SPEECH registry study
Yuxiong Jiang, Xiaoke Liu, Lingling Yao, Dawei Huang, Xiaoyuan Zhong, Yu Wang, Ying Li, Jiajing Lu, Qian Yu, Yuling Shi
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):e470-e472.
PMID: 39520223 DOI: 10.1111/jdv.20428
30.抗IL-36受体单克隆抗体Recibokibart治疗泛发性脓疱性银屑病：1b期临床试验
Recibokibart, an anti-IL-36 receptor monoclonal antibody, for treating generalized pustular psoriasis: Phase 1b trial
Qiaoxia Qian, Baoqi Yang, Xueyan Lu , Zhaoxia Zhang , Jiaqi Chen , Yehong Kuang , Chunlei Zhang , Xiaoyong Man , Juan Su , Chi Ma , Guodong Zhou , Benke Li , Xiaolu Situ , Xiuqiang Ma , Yongming Yang , Yujie Feng , Shi Chen , Yifan Zhan , Qian Chen , Xiangyang Zhu , Jiucun Wang, Furen Zhang
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):e544-e546.
PMID: 39754490
PMCID: PMC12105414
DOI: 10.1111/jdv.20511
31.恶性梅毒：二期梅毒的罕见表现
Syphilis maligna: Uncommon presentation of secondary syphilis
Hui-En Chuo , Yu-Hung Wu
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):1192.
PMID: 39927700 DOI: 10.1111/jdv.20593
32.迈向更全面的评估：解决度普利尤单抗研究与妊娠结局之间的局限性
Towards a more comprehensive evaluation: Addressing limitations in the study of dupilumab and pregnancy outcomes
Lei Zhang, Ziyi Wang, Jun Li , Yaling Li
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):e558-e559.
PMID: 39898753 DOI: 10.1111/jdv.20572
33.Q开关亚历山大石激光联合局部雷帕霉素治疗22例激光难治性面部咖啡因斑
Q-switched alexandrite laser combined with topical rapamycin in 22 patients with laser-resistant facial café-au-lait macules
Xumei Wu, Chaoyang Miao, Yuanxiang Liu, Xinrong Zhao, Yimeng Zhang, Zigang Xu
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):e482-e484.
PMID: 39564867 DOI: 10.1111/jdv.20413
34.中国男男性行为者中沙眼衣原体的感染与基因型分布：一项全国性社区研究
Infections and genotypes of Chlamydia trachomatis among men who have sex with men in China: A nationwide community-based study
Ting-Ting Jiang, Ning-Xiao Cao, Wan-Yue Zhang , Xing-Dong Ye , Yu-Mao Cai , Min-Zhi Wu , Ai-Li Li , Zhan-Feng Han , Yi Zheng , Hai-Bo Ding,Li-Qin Gu,Hong-Chun Liao,Li Yan,Quan Luo , Yun-Qing Yang , Mei-Qin Shi, Yan Han , Yue-Ping Yin, Xiang-Sheng Chen
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):e520-e523.
PMID: 39666450 DOI: 10.1111/jdv.20487
35.关于痤疮治疗中皮肤科化妆品使用建议的国际专家共识
International expert consensus recommendations for the use of dermocosmetics in acne
Diane Thiboutot , Alison M Layton , Ibrahima Traore , Gabriel Gontijo , Patricia Troielli , Qiang Ju , Ichiro Kurokawa , Brigitte Dreno
J Eur Acad Dermatol Venereol. 2025 May;39(5):952-966.
PMID: 38877766
PMCID: PMC12023719
DOI: 10.1111/jdv.20145
36.局部使用4%米诺环素泡沫剂（FMX101）治疗中国中重度寻常痤疮受试者的疗效与安全性：一项3期、多中心、随机、双盲、载体对照研究
Efficacy and safety of topical minocycline foam (FMX101 4%) in treatment of Chinese subjects with moderate-to-severe facial acne vulgaris: A phase , multi-centre, randomized, double-blind, vehicle-controlled study
Yan Le , Wenlin Yang , Jianyun Lu , Xian Jiang , Qing Guo , Chunyun Huang , Qing Sun , Huiping Wang , Mingye Bi , Haiying Wang , Songmei Geng,Bin Yang,Ai-E Xu,Yong Cui,Xiaoyong Man,Yi Zhao,Litao Zhang,Linfeng Li,Zhiqiang Song,Jin Chen,Hao Cheng,Wei Zhu,Xiuping Han,Shanshan Li,Tong Lin,Chunlei Zhang,Jiuhong Li,Yanling Li,Yangfeng Ding,Linda Wang,Yuefang Zhu,Leihong Xiang
J Eur Acad Dermatol Venereol. 2025 May;39(5):967-975.
PMID: 38948962 DOI: 10.1111/jdv.20159
37.对《增强多模态深度学习以提高医学诊断的精确性和效率》的回应
Response to 'Enhancing multimodal deep learning for improved precision and efficiency in medical diagnostics'
Kaili Chen , Zhi Yang , Qianwen Li , Hai Long , Rong Xiao , Kai Hu , Haijing Wu , Qianjin Lu
J Eur Acad Dermatol Venereol. 2025 May;39(5):e453-e455.
PMID: 39305063 DOI: 10.1111/jdv.20347
38.提升黑色素瘤评估HFUS准确性：人工智能与统计精确度的作用
Enhancing HFUS accuracy in melanoma assessment: The role of artificial intelligence and statistical precision
I Chen , S Yu
J Eur Acad Dermatol Venereol. 2025 May;39(5):e460-e461.
PMID: 39501656 DOI: 10.1111/jdv.20419
39.阿布昔替尼治疗结节性痒疹的临床疗效与安全性特征
Abrocitinib for prurigo nodularis: Clinical efficacy and safety profile
Changchun Wang, Quanhong Zhang, Lang Yu, Liuqing Chen, Jinbo Chen
J Eur Acad Dermatol Venereol. 2025 Apr;39(4):e344-e346.
PMID: 39264711 DOI: 10.1111/jdv.20322
40.H1抗组胺药诱发的反常性荨麻疹的诊断检查
Diagnostic workup in paradoxical urticaria induced by H1-antihistamines
Yi-Kui Xiang, Emek Kocatürk
J Eur Acad Dermatol Venereol. 2025 Apr;39(4):723-724.
PMID: 40130384
PMCID: PMC11934000
DOI: 10.1111/jdv.20523
41.接受利妥昔单抗治疗的天疱疮患者长期完全缓解的相关因素
Factors associated with long-term complete remission in pemphigus patients receiving rituximab therapy
Hao-Chen Hsu , Po-Wei Huang, Yung-Tsu Cho , Chia-Yu Chu
J Eur Acad Dermatol Venereol. 2025 Apr;39(4):e313-e316.
PMID: 39150314 DOI: 10.1111/jdv.20290
42.佩索利单抗治疗Netherton综合征
Treatment of Netherton syndrome with spesolimab
Juan Bai , Xinyi Chen , Jianjun Qiao , Hong Fang
J Eur Acad Dermatol Venereol. 2025 Mar;39(3):e261-e262.
PMID: 39073211 DOI: 10.1111/jdv.20244
43.奥法妥木单抗与全身性皮质类固醇联合治疗天疱疮的疗效评估：一项多中心队列研究
Evaluation of combination therapy with ofatumumab and systemic corticosteroids for pemphigus: A multi-centre cohort study
Jing Mao, Siyi Bao, Ying Chen, Zheyu Zhuang , Wenyun Chen , Guomin Li , Zhili Wu , Shiling Geng , Haiqing Wang , Hui Ke, Qiuyun Xu , Niu Xiang , Ying Zou , Zhuo Liu , Lihong Chen , Xia Xiong , Bo Cheng , Ruzeng Xue , Ting Gong , Chao Ji
J Eur Acad Dermatol Venereol. 2025 Mar;39(3):e244-e247.
PMID: 38994899 DOI: 10.1111/jdv.20245
44.阿布昔替尼与度普利尤单抗在成人特应性皮炎患者中的药物生存率比较
Drug survival of abrocitinib compared to dupilumab in adult patients with atopic dermatitis
Qingjie Hu , Yingxia Gao , Kang Xu , Xu Yao
J Eur Acad Dermatol Venereol. 2025 Mar;39(3):e269-e270.
PMID: 39072802 DOI: 10.1111/jdv.20265
45.穿孔移植可作为白癜风黑素细胞移植后病灶周围晕的辅助治疗
Punch grafting can be used as a supplementary treatment for perilesional halo after melanocyte grafting for vitiligo
Xian Yan Luo , Yun Zhi Zhao , Jian Zhong Peng , Yong Hu , Wen Jia Yang , Aie Xu
J Eur Acad Dermatol Venereol. 2025 Mar;39(3):e258-e260.
PMID: 39032071 DOI: 10.1111/jdv.20252
46.口服托法替布、巴瑞替尼和乌帕替尼单药治疗类固醇抵抗性白癜风：一项前瞻性病例系列研究
Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid-resistant vitiligo: A prospective case series
Yijian Zhu , Zhengzhou Shi , Zhongyi Xu , Suqing Liu , Jian Zhang , Qianqian Wang , Ye Liu , Chengfeng Zhang , Min Jiang , Leihong Xiang
J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e128-e130.
PMID: 38853646 DOI: 10.1111/jdv.20109
47.朗格汉斯细胞：特应性皮炎病理生理学的核心参与者
Langerhans cells: Central players in the pathophysiology of atopic dermatitis
Yi Pan, Mathias Hochgerner , Małgorzata Anna Cichoń , Theresa Benezeder , Thomas Bieber, Peter Wolf
J Eur Acad Dermatol Venereol. 2025 Feb;39(2):278-289.
PMID: 39157943
PMCID: PMC11760705
DOI: 10.1111/jdv.20291
48.评估生物制剂在银屑病合并恶性肿瘤患者中的安全性和有效性：见解与未来方向
Evaluating the safety and efficacy of biologics in psoriatic patients with malignancies: Insights and future directions
Sebastian Yu, James Cheng-Chung Wei
J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e191-e192.
PMID: 38932645 DOI: 10.1111/jdv.20195
49.克立硼罗局部给药改善特应性皮炎患者的度普利尤单抗面部皮炎：一项开放标签病例系列研究
Dupilumab facial dermatitis in atopic dermatitis patients ameliorated by topical crisaborole: An open-label case series study
Han-Wen Lin, Wen-Hung Chung, Chun-Bing Chen
J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e181-e183.
PMID: 39105558 DOI: 10.1111/jdv.20281
50.视黄酸通过Wnt/β-连环蛋白信号通路驱动雄激素性脱发中毛囊干细胞的活化
Retinoic acid drives hair follicle stem cell activation via Wnt/β-catenin signalling in androgenetic alopecia
Lihong Wen, Zhexiang Fan , Weichang Huang , Yong Miao , Jiarui Zhang , Bingcheng Liu , Decong Zhu , Damao Dai , Jiaxian Zhang , Demengjie Le , Yufan Zhang , Qian Qu , Zhiqi Hu , Ruosi Chen
J Eur Acad Dermatol Venereol. 2025 Jan;39(1):189-201.
PMID: 38629345
PMCID: PMC11664453
DOI: 10.1111/jdv.20000
52.巴瑞替尼治疗儿童严重斑秃
Baricitinib therapy for paediatric patients with severe alopecia areata
Min Zhao , Yi Wei , Lu Cai , Jia Zhuo , Zhongyu Zhang , Mao Lin
J Eur Acad Dermatol Venereol. 2025 Jan;39(1):e82-e83.
PMID: 38775417 DOI: 10.1111/jdv.20108
53.基于专家共识和分布特征的大型至巨大先天性黑素细胞痣最佳分类系统
A BEST classification system of large to giant congenital melanocytic nevi based on expert consensus and distribution characteristics
Ge Song, Tao Dai , Yajie Chang , Huile Pei , Wuping Liu , Pengfei Guo , Yongqiang Ren , Guiping Shen , Jianghua Feng
J Eur Acad Dermatol Venereol. 2025 Jan;39(1):171-180.
PMID: 38708780 DOI: 10.1111/jdv.20075
54.探究AP1B1相关KIDAR综合征中Th17相关炎症反应及司库奇尤单抗的潜在治疗意义
Exploring Th17-related inflammation in AP1B1-associated KIDAR syndrome and potential therapeutic implications of secukinumab
Chaolan Pan, Hongsong Ge , Luyao Zheng , Qiaoyu Cao , Cheng Zhang , Yumeng Wang, Anqi Zhao, Wei He , Guofang Li, Haifei Liu, Yijun Yang, Ruoqu Wei, Haoyu Wang, Yidong Tan, Bing Wang, Wenjie Cheng, Zhe Sun, Xiaoxiao Wang , Ming Li
J Eur Acad Dermatol Venereol. 2025 Jan;39(1):e13-e16.
PMID: 38641987 DOI: 10.1111/jdv.20033
55.乌帕替尼治疗由NIPAL4变异引起的常染色体隐性遗传性先天性鱼鳞病
Treatment of autosomal recessive congenital ichthyosis caused by a NIPAL4 variant with upadacitinib
Zhuoqing Gong, Yu Wang , Xingyuan Jiang , Huijun Wang , Zhimiao Lin
J Eur Acad Dermatol Venereol. 2025 Jan;39(1):e91-e93.
PMID: 38808853 DOI: 10.1111/jdv.20130
56.全基因组测序揭示中国家族中与Bazex-Dupre-Christol综合征相关的Xq26.1基因间重复序列
Whole genome sequencing revealing Xq26.1 intergenic duplications associated with Bazex-Dupré-Christol syndrome in a Chinese family
An-Qi Zhao, Zhen-Zhen Wang, Sheng-Li Chen, Hong Liu
J Eur Acad Dermatol Venereol. 2025 Jan;39(1):e46-e49.
PMID: 38713094 DOI: 10.1111/jdv.20064
2025年度JID合集列表
（最新IF：5.7）
1.多组学分析揭示寻常痤疮的遗传机制与治疗靶点
Multi-Omics Analysis Identifies Genetic Mechanisms and Therapeutic Targets for Acne Vulgaris
Xinlan Qiu, Yibo Feng, Xiaohui Mo, Qiang Ju
J Invest Dermatol. 2025 Dec;145(12):3037-3050.
PMID: 40398594 DOI: 10.1016/j.jid.2025.04.032
2.中国人群手部湿疹的临床特征及其与特应性皮炎的关联：一项多中心横断面研究
Clinical Characteristics of Hand Eczema and its Association with Atopic Dermatitis in the Chinese Population: A Multicenter Cross-Sectional Study
Junfen Zhang, Yixin Yu, Peizhen Zhao, Liyan Yuan, Xuan Wang, Jingjing Gu, Fei Hao, Gang Wang, Qianjin Lu, Hengjin Li, Jie Zheng, Furen Zhang, Wei Lai, Hongzhong Jin, Xiaoming Liu, Qing Sun, Qing Guo, Liuqing Chen, Yan Ding, Xiaojing Kang, Jie Li, Yuye Li, Yumei Liu, Chengzhi Lv, Shuqing Mei, Zhiqiang Song, Jianqin Wang, Ting Xiao, Wenlin Yang, Xu Yao, Ying Zou, Yunsheng Liang, Bin Yang
J Invest Dermatol. 2025 Dec;145(12):3089-3099.e7.
PMID: 40398595 DOI: 10.1016/j.jid.2025.04.031
3.微针介导的甲氨蝶呤皮内递送通过抑制IL-17A+Vγ4+γδT细胞缓解咪喹莫特诱导的初始及复发性银屑病样皮肤炎症
Microneedle-Mediated Intradermal Delivery of Methotrexate Alleviates Imiquimod-Induced Initial and Recurrent Psoriasis-Like Skin Inflammation by Inhibiting IL-17A+Vγ4+ γδT Cells
Hongyao Du, Jing Yang, Pei Liu, Liang Zhao, Yan Li, Lianbin Zhang, Jintao Zhu, Juan Tao
J Invest Dermatol. 2025 Dec;145(12):3227-3231.e6.
PMID: 40571155 DOI: 10.1016/j.jid.2025.05.039
4.非性激素在女性型脱发发病机制中的新作用
A New Role of Non-Sex Hormone in the Pathogenesis of Female Pattern Hair Loss
Tyng-Shiuan Hsieh, Wei-Hung Wang, Sung-Jan Lin
J Invest Dermatol. 2025 Dec;145(12):2930-2932.
PMID: 40844442 DOI: 10.1016/j.jid.2025.06.1595
5.Piezo1介导的钙离子流将机械信号传递至Yes相关蛋白以刺激瘢痕疙瘩基质生成
Piezo1-Mediated Calcium Flux Transfers Mechanosignal to Yes-Associated Protein to Stimulate Matrix Production in Keloid
Caihe Liao, Peiru Wang, Qingyu Zeng, Guorong Yan, Jiawen Gao, Jia Liu, Jia Yan, Guolong Zhang, Yeqiang Liu, Xiuli Wang
J Invest Dermatol. 2025 Nov;145(11):2869-2881.e9.
PMID: 40254148 DOI: 10.1016/j.jid.2025.03.039
6.协同靶向TGF-β1/SMAD2信号通路治疗雄激素性脱发
miR-574-3p and miR-125a-5p in Adipose-Derived Mesenchymal Stem Cell Exosomes Synergistically Target TGF-β1/SMAD2 Signaling Pathway for the Treatment of Androgenic Alopecia
Cong Ma, Ming Cheng, Ting Xiao, Ruiqun Qi, Xinghua Gao, Hongduo Chen, Yan Wu, Xuegang Xu
J Invest Dermatol. 2025 Nov;145(11):2719-2735.e3.
PMID: 40306482 DOI: 10.1016/j.jid.2025.03.042
7.中国皮肤白化病患者TYR变异效应的多重检测与再分类
Multiplexed Assays of Variant Effect and Reclassification of TYR Variants in Chinese Patients with Oculocutaneous Albinism
Shushu Lv, Zhenhua Hao, Wei Li, Aihua Wei
J Invest Dermatol. 2025 Nov;145(11):2798-2810.e5.
PMID: 40252993 DOI: 10.1016/j.jid.2025.03.038
8.提升银屑病与炎症性皮肤病的诊断水平：一种整合临床与皮肤镜图像的空间对齐多模态模型
Enhancing Diagnosis of Psoriasis and Inflammatory Skin Diseases: A Spatially Aligned Multimodal Model Integrating Clinical and Dermoscopic Images
Juncheng Wang, Yilan Zhang, Fengying Xie, Jie Liu
J Invest Dermatol. 2025 Nov;145(11):2736-2744.e6.
PMID: 40216156 DOI: 10.1016/j.jid.2025.03.034
9.探索年轻成年女性早发性白发的危险因素：一项在中国上海开展的横断面研究
Exploring the Risk Factors for Premature Hair Graying in Young Adult Women: A Cross-Sectional Study in Shanghai, China
Wen-Cai Jiang, Hui Zhang, Ya-Fei Xu, Hai-Mei Kong, Yi-Mei Tan, Da-Ru Lu
J Invest Dermatol. 2025 Nov;145(11):2882-2885.e4.
PMID: 40387682 DOI: 10.1016/j.jid.2025.03.027
10.耐受性单核细胞来源的朗格汉斯细胞通过芳烃受体-环氧合酶-2激活促进黑色素瘤进展及免疫治疗耐药
Tolerogenic Monocyte-Derived Langerhans Cells Promote Melanoma Progression and Immunotherapy Resistance through Aryl Hydrocarbon Receptor-Cyclooxygenase-2 Activation
Liyun Dong, Naming Wu, Zhen Cai, Shiyi Yan, Juan Pan, Liu Yang, Jinjin Zhu, Yujue Wang, Jun Li, Juan Tao
J Invest Dermatol. 2025 Nov;145(11):2828-2838.e10.
PMID: 40216154 DOI: 10.1016/j.jid.2025.02.155
11.内皮Piezo1介导银屑病中屏障功能障碍与NLRP3炎症小体激活
Endothelial Piezo1 Mediates Barrier Dysfunction and NLRP3 Inflammasomes Activation in Psoriasis
Lixin Yue, Bingyu Pang, Guohao Li, Chen Zhang, Qingyang Li, Kang Li, Hui Fang, Zhenlai Zhu, Shuai Shao, Erle Dang, Gang Wang, Pei Qiao
J Invest Dermatol. 2025 Oct;145(10):2484-2494.e5.
PMID: 40054572 DOI: 10.1016/j.jid.2025.01.037
12.瘢痕疙瘩形成中的内皮功能障碍及其治疗启示
Endothelial Dysfunction in Keloid Formation and Therapeutic Insights
Junxian Wen, Zhijin Li, Yingrou Tan, Hong Liang Tey, Nanze Yu, Xiaojun Wang
J Invest Dermatol. 2025 Oct;145(10):2436-2448.
PMID: 40100176 DOI: 10.1016/j.jid.2025.02.134
13.USP7介导的泛素化稳定JunD并激活AIFM2（FSP1）以抑制黑色素瘤铁死亡
Deubiquitination by USP7 Stabilizes JunD and Activates AIFM2 (FSP1) to Inhibit Ferroptosis in Melanoma
Jiaheng Xie, Chenfeng Ma, Songyun Zhao, Dan Wu, Pengpeng Zhang, Qikai Tang, Tianyi Ni, Wei Yan, Min Qi
J Invest Dermatol. 2025 Oct;145(10):2562-2575.e5.
PMID: 40187679 DOI: 10.1016/j.jid.2025.03.018
14.情绪困扰与特应性皮炎的关联性：一项横断面研究
Association between Emotional Distress and Atopic Dermatitis: A Cross-Sectional Study
Hanyi Zhang, Siding Tang, Xiang Chen, Mi Wang, Juan Su
J Invest Dermatol. 2025 Oct;145(10):2613-2615.e1.
PMID: 40139563 DOI: 10.1016/j.jid.2025.03.007
15.基底外侧杏仁核至内侧前额叶皮层的谷氨酸能投射参与急性瘙痒感觉处理
Glutamatergic Projections from the Basolateral Amygdala to Medial Prefrontal Cortex Contribute to Acute Itch Sensation Processing
Qiuying Zhao, Ze Fan, Yiwen Zhang, Jiaqi Li, Yuanyuan Zhu, Yiting Lin, Qingrong Ni, Xiaotong Shi, Ling Liu, Shengxi Wu, Jing Huang
J Invest Dermatol. 2025 Oct;145(10):2588-2597.
PMID: 40043789 DOI: 10.1016/j.jid.2025.02.138
16.血转录组特征作为阿布昔替尼治疗特应性皮炎的疗效指标与预测因子
Blood Transcriptome Signature as Indicator and Predictor for Efficacy of Abrocitinib in Treatment of Atopic Dermatitis
Yu Wang, Huibin Yin, Zheng Li, Hao Wu, Qianhao Wang, Xingyu Chen, Liya Mao, Yuemeng Wu, Shangshang Wang, Haihong Qin, Chaoying Gu, Xu Yao, Wei Li
J Invest Dermatol. 2025 Oct;145(10):2524-2534.e5.
PMID: 40058571 DOI: 10.1016/j.jid.2025.02.145
17.基于人工智能模型的银屑病患者体表面积精确测量方法开发
Development of an Artificial Intelligence-Based Model to Precisely Measure Body Surface Area in Psoriasis
Yiyi Wang, Xuhao Wang, Xinran Ming, Yuanxia Gu, Qian Wang, Mingzheng Zhu, Lin Qin, Furong Li, Yue Xiao, Hongxiang Hu, Chenlin Du, Yue Zhang, Mingyue Zhang, Ranjie Hu, Wei Li
J Invest Dermatol. 2025 Oct;145(10):2600-2602.e6.
PMID: 40158769 DOI: 10.1016/j.jid.2025.03.013
18.与银屑病发病机制相关的记忆辅助性T细胞和记忆调节性T细胞的转录组及染色质景观变化
Transcriptome and Chromatin Landscape Changes Associated with Pathogenesis of Psoriasis in Memory T Helper and Memory Regulatory T Cells
Mengyun Chen, Min Chen, Lu Liu, Pengcheng Yan, Ziyuan Meng, Tingting Zhu, He Huang, Weiran Li, Xuejun Zhang, Zheng Zhang, Bo Zhang
J Invest Dermatol. 2025 Oct;145(10):2606-2609.e6.
PMID: 40187680 DOI: 10.1016/j.jid.2025.03.019
19.5-氨基酮戊酸光动力疗法通过蛋白激酶B/JunD介导的NR4A1激活调节脂质生成治疗寻常痤疮
The 5-Aminolevulinic Acid Photodynamic Therapy Modulates Lipid Production by Protein Kinase B/JunD-Mediated NR4A1 Activation in the Treatment of Acne Vulgaris
Yun Wu , Xiaojing Liu , Linglin Zhang , Peiru Wang , Haiyan Zhang , Jia Yan , Yu Yan , Pei Liu , Jingjun Zhao , Qingyu Zeng , Xiuli Wang
J Invest Dermatol. 2025 Sep;145(9):2179-2190.e2.
PMID: 39922453 DOI: 10.1016/j.jid.2025.01.018
20.寻常痤疮多组学研究进展:文献综述
Progress on Multiomics Research on Acne Vulgaris: A Literature Review
Yangfan Lai , Mengjie Fan , Xiaoyao Fan , Jin Chen , Leihong Flora Xiang , Ying Ma
J Invest Dermatol. 2025 Sep;145(9):2162-2169.
PMID: 40146096 DOI: 10.1016/j.jid.2025.02.012
21.银屑病文献研究热点与趋势识别：基于Agent的自动调谐主题建模
Identifying Research Hotspots and Trends in Psoriasis Literature: Autotuned Topic Modeling with Agent
Sunsi Wu , Dan Wang , Xinpei Gu , Ruiheng Xiao , Hongzhi Gao , Bo Yang , Yanlan Kang
J Invest Dermatol. 2025 Sep;145(9):2210-2218.e14.
PMID: 39894203 DOI: 10.1016/j.jid.2024.11.029
22.网状细胞与角质形成细胞串扰在皮肤免疫中的作用
The Role of Crosstalk between Nets and Keratinocytes in Skin Immunity
Xiao Zhou , Yi Jin , Yanshan Zhu , Xin Luo , Siying Li , Weiyun Shen , Ruifang Wu
J Invest Dermatol. 2025 Aug;145(8):1866-1878.
PMID: 39985552 DOI: 10.1016/j.jid.2024.07.040
23.表皮机械搔抓诱导的活性氧通过激活肥大细胞上的TRPA1加剧特应性皮炎的瘙痒-搔抓循环
Epidermal Mechanical Scratching-Induced ROS Exacerbates the Itch-Scratch Cycle through TRPA1 Activation on Mast Cells in Atopic Dermatitis
Jiahui Hu , Qiang Zhao , Delu Che , Bin Peng , Xi Wang , Kathy Wang , Li Li , Songmei Geng
J Invest Dermatol. 2025 Aug;145(8):2034-2048.e7.
PMID: 39892773 DOI: 10.1016/j.jid.2024.12.026
24.下调的TFPI2通过磷酸肌醇3-激酶/蛋白激酶B/CDC6通路抑制细胞周期从而加速皮肤衰老
Downregulated TFPI2 Accelerates Skin Aging by Repressing the Cell Cycle through Phosphoinositide 3-Kinase/Protein Kinase B/CDC6 Pathway
Fan Wang , Caitan Yi , Yun Zhong , Lei Zhou , Xin Meng , Rui Mao , Yi Guo , Hongfu Xie , Yiya Zhang , Yingxue Huang , Ji Li
J Invest Dermatol. 2025 Aug;145(8):1910-1920.e7.
PMID: 39848565 DOI: 10.1016/j.jid.2024.11.028
25.先天性大/巨黑素细胞痣与卫星痣关系的探讨
Insight into the Relationship between Congenital Large/Giant Melanocytic Nevi and Satellite Nevi
Jieyu Gu , Boxuan Wei , Ran Duan , Jiamin Jin , Bohan Lai , Jiao Wei , Feng Xie
J Invest Dermatol. 2025 Aug;145(8):2071-2074.e2.
PMID: 39890054 DOI: 10.1016/j.jid.2024.10.620
26.重度痤疮家族的全基因组结构变异研究
Whole-Genome Structural Variations Study in a Severe Acne Family
Jiaqi Feng , Mingmin Xu , Jue Qi , Wenjuan Wu , Minsheng Peng , Li He
J Invest Dermatol. 2025 Aug;145(8):2098-2102.e5.
PMID: 39952348 DOI: 10.1016/j.jid.2025.01.023
27.革新慢性伤口治疗：采用三维生物打印皮肤替代物治疗博来霉素病灶内注射相关慢性伤口
Revolutionizing Chronic Wound Treatment: Treating Bleomycin Intralesional Injection-Related Chronic Wounds with 3-Dimensional Bioprinted Skin Substitutes
Mengde Zhang , Zhao Li , Rungong Yang , Liting Liang , Yuyan Huang , Chao Zhang , Yaxin Tan , Yuzhe Bai , Xiaobing Fu , Sha Huang
J Invest Dermatol. 2025 Aug;145(8):2111-2114.e7.
PMID: 39800166 DOI: 10.1016/j.jid.2024.12.018
28.表皮功能障碍在炎症衰老发病机制中的作用与意义
The Role and Implications of Epidermal Dysfunction in the Pathogenesis of Inflammaging
Jiechen Zhang , Bijun Xia , Joan S Wakefield , Peter M Elias , Xiaohua Wang
J Invest Dermatol. 2025 Jul;145(7):1580-1588.
PMID: 39808093 DOI: 10.1016/j.jid.2024.09.025
29.低密度中性粒细胞水平与孢子丝菌病严重程度相关：皮下真菌感染的深入研究
Low-Density Neutrophil Levels Are Correlated with Sporotrichosis Severity: Insights into Subcutaneous Fungal Infection
Ying Shi , Yuan-Yuan Liu , Yu Zhen , He-Nan Si , Meng-Qi Guan , Yan Cui , Shan-Shan Li
J Invest Dermatol. 2025 Jul;145(7):1753-1769.e3.
PMID: 39603410 DOI: 10.1016/j.jid.2024.10.610
30.光与影之间：白癜风非病灶皮肤的谜团
Between Light and Shadow: The Enigma of Nonlesional Skin in Vitiligo
Yijian Zhu , Chengfeng Zhang
J Invest Dermatol. 2025 Jul;145(7):1547-1549.
PMID: 40257415 DOI: 10.1016/j.jid.2025.02.011
31.血管紧张素转换酶抑制剂与皮肤纤维化风险无因果关联：孟德尔随机化证据
No Causal Association between Angiotensin-Converting Enzyme Inhibitors and Skin Fibrosis Risk: Evidence from Mendelian Randomization
Yangyang Wei , Ziqi Wan , Yiwen Jiang , Zhengye Liu , Ming Yang , Jieying Tang
J Invest Dermatol. 2025 Jul;145(7):1808-1810.e3.
PMID: 39814197 DOI: 10.1016/j.jid.2024.12.020
32.雄激素性脱发与中国重症急性呼吸综合征冠状病毒2 Omicron变异株感染的相关性
Correlation between Androgenetic Alopecia and Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Infection in China
Shuying Lv , Xiaohui Zou , Lei Wang , Yonglong Xu , Chuhan Huang , Shiyi Zhong , Wenjun Lin , Ying Xie , Huijuan Fang , Meijiao Du , Yunran Cui , Ruiying Wu , Yuqi Jiang , Mingyue Zhuang , Jieping Huang , Dingquan Yang
J Invest Dermatol. 2025 Jul;145(7):1633-1642.e6.
PMID: 39725159 DOI: 10.1016/j.jid.2024.11.013
33.头皮屑患者头皮微生物氨基酸代谢异常及发病机制
Abnormal Microbial Amino Acid Metabolism and Activated Pathogenesis in Scalp with Dandruff
Zhijue Xu , Fang Yang , Baoyu Xiang , Xiaowei Chang , Dandan Xia , Yaoyao Wu , Yan Zhang , Menghui Zhang
J Invest Dermatol. 2025 Jul;145(7):1823-1826.e7.
PMID: 39842690 DOI: 10.1016/j.jid.2025.01.006
34.ADAM10/17介导的LAG3切割在银屑病免疫抑制功能障碍中的作用
Role of ADAM10/17-Mediated Cleavage of LAG3 in the Impairment of Immunosuppression in Psoriasis
Zengyang Yu , Xinyi Tang , Zeyu Chen , Yifan Hu , Shuqin Zhang , Chunyuan Guo , Jun Gu , Yuling Shi , Yu Gong
J Invest Dermatol. 2025 Jun;145(6):1385-1395.e8.
PMID: 39571889 DOI: 10.1016/j.jid.2024.10.606
35.铁死亡：黑色素瘤治疗的可靶向弱点
Ferroptosis: A Targetable Vulnerability for Melanoma Treatment
Yu Meng , Qian Zhou , Yating Dian , Furong Zeng , Guangtong Deng , Xiang Chen
J Invest Dermatol. 2025 Jun;145(6):1323-1344.
PMID: 39797894 DOI: 10.1016/j.jid.2024.11.007
36.早期阶段顶泌腺损伤及特异性角蛋白释放表明顶泌腺在化脓性汗腺炎中的关键作用
Apocrine Gland Damage and the Release of Specific Keratins in Early Stage Indicate the Crucial Involvement of Apocrine Glands in Hidradenitis Suppurativa
Jiaqi Li , Sitong Li , Qiujing Zhang , Mengchen Liang , Xiang Chen , Yibo Feng , Zhanyan Pan , Tingting Hu , Qiong Wu , Guangjie Chen , Christos C Zouboulis , Xiaohui Mo , Qiang Ju
J Invest Dermatol. 2025 Jun;145(6):1371-1384.e7.
PMID: 39547394 DOI: 10.1016/j.jid.2024.09.021
37.海藻糖通过抑制IL-33表达及增强NRF2活化，预防IL-4/IL-13在体外诱导的人角质形成细胞皮肤屏障功能障碍
Trehalose Prevents IL-4/IL-13-Induced Skin Barrier Impairment by Suppressing IL-33 Expression and Increasing NRF2 Activation in Human Keratinocytes In Vitro
Xiuju Dai , Yoichi Mizukami , Kenji Watanabe , Teruko Tsuda , Mutsumi Shidahara , Satoshi Yoshida , Kazuki Yatsuzuka , Ken Shiraishi , Hideki Mori , Masamoto Murakami , Ryosuke Kawakami , Takeshi Imamura , Yasuhiro Fujisawa , Jun Muto
J Invest Dermatol. 2025 Jun;145(6):1422-1432.e10.
PMID: 39384017 DOI: 10.1016/j.jid.2024.08.038
38.干预CCL8-CCR8信号通路可减轻小鼠皮肤炎症与瘙痒
Intervening CCL8-CCR8 Signaling Reduces Cutaneous Inflammation and Itch in Mice
Huiyuan Mei , Xiaolong Dai , Weiwei Chen , Rengang Luo , Yang Liu , Jianghui Meng , Jiafu Wang
J Invest Dermatol. 2025 Jun;145(6):1519-1523.e4.
PMID: 39761909 DOI: 10.1016/j.jid.2024.12.012
39.化脓性汗腺炎中三级淋巴组织的解码：新的机制性见解
Decoding Tertiary Lymphoid Structures in Hidradenitis Suppurativa: New Mechanistic Insights
Wei-Wen Yu , Jie Tong , Catherine P Lu
J Invest Dermatol. 2025 Jun;145(6):1272-1274.
PMID: 40152835 DOI: 10.1016/j.jid.2025.01.026
40.皮肤驻留γδ T细胞通过定向趋化迁移及细胞毒性颗粒动员介导强效选择性抗肿瘤细胞毒性
Skin-Resident γδ T Cells Mediate Potent and Selective Antitumor Cytotoxicity through Directed Chemotactic Migration and Mobilization of Cytotoxic Granules
Jiacai Yang , Zhihui Liu , Xiaohong Hu , Xiaorong Zhang , Yong Huang , Yunxia Chen , Cheng Chen , Ruoyu Shang , Yuanyang Tang , Wengang Hu , Jue Wang , Han-Ming Shen , Jun Hu , Weifeng He
J Invest Dermatol. 2025 Jun;145(6):1433-1446.e2.
PMID: 39571888 DOI: 10.1016/j.jid.2024.10.607
41.优化皮肤表面代谢组学：采样方法、提取溶剂与分析技术的综合评估
Optimizing Skin Surface Metabolomics: A Comprehensive Evaluation of Sampling Methods, Extraction Solvents, and Analytical Techniques
Huizhen Chen , Yu Chen , Yi Zhou , Shensong Cao , Jing Lu , Lianyi Han , Thomas Worzfeld , Jean Krutmann , Jiucun Wang , Jingjing Xia
J Invest Dermatol. 2025 May;145(5):1166-1179.
PMID: 39306031 DOI: 10.1016/j.jid.2024.08.027
42.解析糖尿病伤口愈合过程中成纤维细胞功能中IGF-1-SP1-CD248通路的失调机制
Deciphering the Dysregulating IGF-1-SP1-CD248 Pathway in Fibroblast Functionality during Diabetic Wound Healing
Ya-Chu Ku , Yao-Chou Lee , Yi-Kai Hong , Yung-Ling Lo , Cheng-Hsiang Kuo , Kuan-Chieh Wang , Chao-Kai Hsu , Chien-Hung Yu , Shu-Wha Lin , Hua-Lin Wu
J Invest Dermatol. 2025 May;145(5):1180-1195.
PMID: 39293711 DOI: 10.1016/j.jid.2024.07.035
43.内在调节机制保护人类皮肤肥大细胞免受MRGPRX2过度激活：LAD2（过敏性疾病实验室2）细胞中该受体的缺乏导致肥大细胞高反应性
Intrinsic Regulatory Mechanisms Protect Human Skin Mast Cells from Excessive MRGPRX2 Activation: Paucity in LAD2 (Laboratory of Allergic Diseases 2) Cells Contributes to Hyperresponsiveness of the Mast Cell Line
Zhuoran Li , Jean Schneikert , Gürkan Bal , Manqiu Jin , Kristin Franke , Torsten Zuberbier , Magda Babina
J Invest Dermatol. 2025 May;145(5):1215-1219.e4.
PMID: 39481529 DOI: 10.1016/j.jid.2024.10.593
44.TRPS1 rs12549956增强子影响中国人群的头发厚度
Enhancer of TRPS1 rs12549956 Influences Hair Thickness in Chinese Populations
Qili Qian , Sijie Wu , Junyu Luo , Yaqun Guan , Yajun Yang , Li Jin , Wenxin Zheng , Sijia Wang
J Invest Dermatol. 2025 May;145(5):1202-1205.e9.
PMID: 39547395 DOI: 10.1016/j.jid.2024.10.601
45.皮肤老化中的G蛋白偶联受体
G Protein-Coupled Receptors in Skin Aging
Suet Ting Cheung , Yelim Do , Eunah Kim , Antonella Rella , Earl Goyarts , Nadine Pernodet , Yung Hou Wong
J Invest Dermatol. 2025 Apr;145(4):749-765.e8.
PMID: 39186022 DOI: 10.1016/j.jid.2024.06.1288
46.FGF21通过抑制CK2α/GLI2信号轴改善成纤维细胞活化与系统性硬化
FGF21 Ameliorates Fibroblasts Activation and Systemic Sclerosis by Inhibiting CK2α/GLI2 Signaling Axis
Yeyi Zheng , Wenjie Gong , Zhaohang Wu , Siyi Zhang , Nan Wang , Zhenyu Hu , Yanni Shou , Tianpeng Xu , Yingjie Shen , Xiaokun Li , Litai Jin , Weitao Cong , Zhongxin Zhu
J Invest Dermatol. 2025 Apr;145(4):842-853.e8.
PMID: 39182559 DOI: 10.1016/j.jid.2024.07.026
47.解析银屑病患者外周血CD4+T细胞的三维基因组景观
Resolving 3-Dimensional Genomic Landscape of CD4+ T Cells in the Peripheral Blood of Patients with Psoriasis
Yueqi Qiu , Wenjuan Jiang , Delong Feng , Yaqin Yu , Huihui Hou , Min Deng , Xiaoyun Chen , Lin Liu , Ruifang Wu , Qianjin Lu , Ming Zhao
J Invest Dermatol. 2025 Apr;145(4):831-841.e10.
PMID: 39182560 DOI: 10.1016/j.jid.2024.08.006
48.抑制脂肪细胞源性FABP4可减轻脂肪细胞炎症、促进血管生成并加速代谢功能障碍中的伤口愈合
Inhibition of Adipocyte-Derived FABP4 Reduces Adipocyte Inflammation, Improves Angiogenesis, and Facilitates Wound Healing in Metabolic Dysfunctions
Yen-Wen Wu , Jaw-Wen Chen , Hao-Yuan Tsai , Jih-Hsin Huang , Chia-Chi Chang , Ting-Ting Chang
J Invest Dermatol. 2025 Apr;145(4):939-953.
PMID: 39260685 DOI: 10.1016/j.jid.2024.08.017
49.抑制表皮异亮氨酰-tRNA合成酶通过Jak2/信号转导与转录激活因子3/CXCL16信号通路改善银屑病样皮肤病变
Inhibition of Epidermal Isoleucyl-tRNA Synthetase Ameliorates Psoriasis-Like Skin Lesions through Jak2/Signal Transducer and Activator of Transcription 3/CXCL16 Signaling Pathway
Xi-Bei Chen , Yu-Xin Zheng , Ting-Ting Guo , Fan Xu , Ying-Zhe Cui , Lei Nie , Hai-Bin Wang , Li-Ran Ye , Ying Liu , Xing-Yu Yang , Ni-Chang Fu , Bin-Xi Yan , Min Zheng , Xiao-Yong Man
J Invest Dermatol. 2025 Apr;145(4):954-958.e8.
PMID: 39293712 DOI: 10.1016/j.jid.2024.08.021
50.Paxbp1是维持表皮稳态不可或缺的因子
Paxbp1 Is Indispensable for the Maintenance of Epidermal Homeostasis
Cong Huang , Shenglin Liu , Wenting Li , Shizheng Zhao , Xuanyao Ren , Fan Zhuo , Kaoyuan Zhang , Xiahong Li , Jingwen Wu , Zimo Zhu , Chao Chen , Wei Zhang , Bo Yu
J Invest Dermatol. 2025 Apr;145(4):864-875.e5.
PMID: 39236903 DOI: 10.1016/j.jid.2024.08.012
51.Chi3l1基因敲除可减轻小鼠慢性瘙痒及皮肤炎症
Chi3l1 Knockout Mitigates Chronic Itch and Cutaneous Inflammation in Mice
Xingyun Zhu , Xiaolong Dai , Weiwei Chen , Yanqing Li , Yang Liu , Chunxu Shan , Jiafu Wang , Jianghui Meng
J Invest Dermatol. 2025 Apr;145(4):975-979.e4.
PMID: 39366519 DOI: 10.1016/j.jid.2024.09.013
52.东亚人群指甲板形态相关基因位点
Genetic Loci Associated with Nail Plate Morphology in East Asian Populations
Jieyu Ge , Mengxiang You , Yu Fan , Yong Zhou , Li Jin , Guangtao Zhai , Fan Liu , Sijia Wang
J Invest Dermatol. 2025 Apr;145(4):969-972.e9.
PMID: 39384015 DOI: 10.1016/j.jid.2024.08.035
53.真菌分泌肽Micasin通过激活外周神经元上的MRGPRX1/C11/A1诱导瘙痒
The Fungal Secretory Peptide Micasin Induces Itch by Activating MRGPRX1/C11/A1 on Peripheral Neurons
Haifeng Yang , Yian Chen , Luyao Wang , Bing Gan , Leiye Yu , Ruobing Ren , Hang Fai Kwok , Yingliang Wu , Zhijian Cao
J Invest Dermatol. 2025 Mar;145(3):618-630.
PMID: 38945438 DOI: 10.1016/j.jid.2024.05.031
54.佩索利单抗减轻泛发性脓疱型银屑病炎症：EFFISAYIL 1中发作期治疗的分子特征
Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1
Ahmed Farag , Sudha Visvanathan , Hervé Bachelez , Akimichi Morita , Mark G Lebwohl , Jonathan N Barker , Siew Eng Choon , A David Burden , Tsen-Fang Tsai , Germán Leparc , Denis Delic , Benjamin Lang , Christian Thoma , James G Krueger
J Invest Dermatol. 2025 Mar;145(3):573-582.e8.
PMID: 39004117 DOI: 10.1016/j.jid.2024.05.034]
55.Neurturin GF增强炎症皮肤的急性细胞因子反应
Neurturin GF Enhances the Acute Cytokine Response of Inflamed Skin
Marsha Ritter Jones , James Jones , Prathyusha Pandu , Chunyan Liu , Cara D Carey , Louis D Falo , Kathryn M Albers
J Invest Dermatol. 2025 Mar;145(3):583-592.
PMID: 39122143 DOI: 10.1016/j.jid.2024.07.016
56.共生皮肤微生物群的细胞外囊泡通过重建皮肤稳态缓解特应性皮炎小鼠模型的皮肤炎症
Extracellular Vesicles of Commensal Skin Microbiota Alleviate Cutaneous Inflammation in Atopic Dermatitis Mouse Model by Re-Establishing Skin Homeostasis
Hong Zhou , Xi Tan , Guozhong Chen , Xinxin Liu , Aiping Feng , Zhi Liu , Wei Liu
J Invest Dermatol. 2025 Feb;145(2):312-322.e9.
PMID: 36907322 DOI: 10.1016/j.jid.2023.02.023
57.SERPINB7缺陷增加Nagashima型掌跖角化病中类豆蛋白酶活性并损害表皮屏障
SERPINB7 Deficiency Increases Legumain Activity and Impairs the Epidermal Barrier in Nagashima-Type Palmoplantar Keratoderma
Siyuan Li , Yingda Wu , Dingfang Bu , Linghan Hu , Yihe Liu , Juan Liu , Ruiyu Xiang , Wenbo Bu , Ran Mo , Zhongya Song , Zhiming Chen , Dongqing Li , Xue Zhang , Heng Gu , Yong Yang
J Invest Dermatol. 2025 Feb;145(2):359-369.e8.
PMID: 38909841 DOI: 10.1016/j.jid.2024.05.025
58.从结果追溯至病因：NRF2驱动的GSTA4转录调控控制特应性皮炎复发中的慢性炎症与氧化应激
Retracing from Outcomes to Causes: NRF2-Driven GSTA4 Transcriptional Regulation Controls Chronic Inflammation and Oxidative Stress in Atopic Dermatitis Recurrence
Xin Ma , Hang Zhao , Jian-Kun Song , Zhan Zhang , Chun-Jie Gao , Ying Luo , Xiao-Jie Ding , Ting-Ting Xue , Ying Zhang , Meng-Jie Zhang , Mi Zhou , Rui-Ping Wang , Le Kuai , Bin Li
J Invest Dermatol. 2025 Feb;145(2):334-345.e11.
PMID: 38879155 DOI: 10.1016/j.jid.2024.05.018
59.婴儿血管瘤发育过程中细胞命运的调控
Cell Fate Regulation During the Development of Infantile Hemangioma
Qiming Chen , Jiawei Zheng , Qian Bian
J Invest Dermatol. 2025 Feb;145(2):266-279.
PMID: 39023471 DOI: 10.1016/j.jid.2024.06.1275
60.局部应用硝酸盐通过调节系统性硬化症小鼠模型中的ST2+CD4+T细胞改善皮肤纤维化
Topical Application of Nitrate Ameliorates Skin Fibrosis by Regulating ST2+CD4+ T Cells in Systemic Sclerosis Mouse Model
Jianyu Gu , Zekun Zhou , Shihan Xu , Wen Pan , Jinsong Wang , Ousheng Liu , Songlin Wang , Junji Xu
J Invest Dermatol. 2025 Feb;145(2):346-358.e5.
PMID: 38945439 DOI: 10.1016/j.jid.2024.06.1273
61.机械牵张加剧咪喹莫特诱导性皮炎并伴随IL-1β和IL-6生成增加
Mechanical Stretch Exacerbates Imiquimod-Induced Dermatitis Associated with Increased IL-1β and IL-6 Production
Chaw-Ning Lee , Yi-Kai Hong , Hui-Ching Cheng , Wan-Yu Chi , Wei-Chen Lin , Chao-Kai Hsu , Yu-Chen Lin , Shu-Yi Cheng , Ming-Jer Tang , Chao-Chun Yang
J Invest Dermatol. 2025 Feb;145(2):436-440.
PMID: 39103118 DOI: 10.1016/j.jid.2024.07.015
62.瘢痕疙瘩潜在药物靶点的鉴定：一项孟德尔随机化研究
Identifying Potential Drug Targets for Keloid: A Mendelian Randomization Study
Yinmin Wang , Xiuxia Wang , Zhaoqi Yuan , Fei Liu , Xusong Luo , Jun Yang
J Invest Dermatol. 2025 Jan;145(1):77-84.e6.
PMID: 38797322 DOI: 10.1016/j.jid.2024.04.023
63.成纤维细胞分泌的外泌体在皮肤伤口愈合过程中调控巨噬细胞极化动态
Orchestration of Macrophage Polarization Dynamics by Fibroblast-Secreted Exosomes during Skin Wound Healing
Cheng Chen , Jiacai Yang , Ruoyu Shang , Yuanyang Tang , Xin Cai , Yunxia Chen , Zhihui Liu , Wengang Hu , Weiguang Zhang , Xiaorong Zhang , Yong Huang , Xiaohong Hu , Wenjing Yin , Qudong Lu , Hao Sheng , Dejiang Fan , Zhenyu Ju , Gaoxing Luo , Weifeng He
J Invest Dermatol. 2025 Jan;145(1):171-184.e6. d
PMID: 38838771 DOI: 10.1016/j.jid.2024.05.007
64.白癜风患者色素再生率的计算机辅助评估：对治疗效果的影响——一项回顾性研究
Computer-Aided Assessment of Repigmentation Rates in Vitiligo Patients: Implications for Treatment Efficacy - A Retrospective Study
Zheng Wang , Hui Hu , Yangyang Ou , Chong Wang , Kejuan Yue , Kaibin Lin , Jiarui Ou , Jianglin Zhang
J Invest Dermatol. 2025 Jan;145(1):56-64.e5.
PMID: 38909840 DOI: 10.1016/j.jid.2024.05.016
65.富含亮氨酸重复序列蛋白15阳性成纤维细胞的双重作用：从癌症到组织修复
The Dual Roles of Leucine-Rich Repeat-Containing Protein 15 Positive Fibroblasts: From Cancer to Tissue Repair
Honglin Zhu , Meng Meng , Hui Luo , Jörg H W Distler
J Invest Dermatol. 2025 Jan;145(1):200-204.e2.
PMID: 38987016 DOI: 10.1016/j.jid.2024.06.1279
2025年度Nature及子刊合集
（最新IF：Nature, 48.5；Nature Communications, 15.7；Nature Immunology, 27.6；Nature Genetics, 29.0；Nature Medicine, 50.0；Nature Aging, 19.4）
1. 以 IL-36/TNFSF15为核心的动态中性粒细胞-角质细胞通讯网络揭示全身性脓疱型银屑病的炎症反应特征
Dynamic neutrophil-keratinocyte communication network centered on IL-36/TNFSF15 responses characterizes inflammatory responses in generalized pustular psoriasis
Jiang R, Kirma J, Fox J, Xing X, Wang J, Sarkar MK, Bogle R, Do T, Coon A, Cole C, Plazyo O, Rew JE, Zhang H, Kahlenberg JM, Billi AC, Bachelez H, Tsoi LC, Harms PW, Shao S, Chen X, Gudjonsson JE.
Nat Commun. 2025 Dec 23. doi: 10.1038/s41467-025-67917-9. Online ahead of print.
PMID: 41436466
2.一种广谱中和抗体通过抑制gB介导的膜融合，对α疱疹病毒属实现跨属保护
A broadly neutralizing antibody confers cross-genus protection against alpha herpesviruses by inhibiting gB-mediated membrane fusion.
Wang G, Li Y, Wu C, Chen T, Gui M, Zeng Y, Sun H, Chen K, Xi X, Yang Y, Jiang Y, Jiang Y, Liu L, Yang C, Xin J, Liu C, Li Y, Huo N, Huang Y, Lin L, Yu H, Huang C, Yuan Q, Li S, Tian K, Zheng Q, Xia N, Chen Y.
Nat Commun. 2025 Dec 16;16(1):11144. doi: 10.1038/s41467-025-66099-8.
PMID: 41402251
3.人多能干细胞衍生皮肤类器官构建了结核分枝杆菌感染的病理生理模型
Human pluripotent stem cell-derived skin organoids enabled pathophysiological model of Mycobacterium tuberculosis infection.
Yue L, Liang Y, Zhong P, Fang L, Yun Z, Su Q, Li C, Xiang M, Zhang J, Wang J, Ge L, Wu C, Chen H, Qiu X, Bo X, Tan Y.
Nat Commun. 2025 Dec 2;16(1):10831. doi: 10.1038/s41467-025-65848-z.
PMID: 41331115
4.疥螨流行病学特征的估算
Estimation of the epidemiological characteristics of scabies.
Ainslie KEC, Hooiveld M, Wallinga J.
Nat Commun. 2025 Nov 26;16(1):10524. doi: 10.1038/s41467-025-65544-y.
PMID: 41298361
5.原生PMEL层状体在黑色素小体中的原子结构及原位可视化
Atomic structure and in situ visualization of native PMEL lamellae in melanosomes.
Ma B, Yao Y, Dong H, Yang L, Li D, Zhao Q, Sun B, Chen Y, Liu C, Li D.
Nat Commun. 2025 Nov 21;16(1):10300. doi: 10.1038/s41467-025-65221-0.
PMID: 41271718
6.用于复制人皮肤纹理的发光纳米纤维
Luminescent nanofibers for human skin textures photocopying.
Tian T, Han H, Lin X, Kang H, Yang M, Chen Z, Wu C, Jiang Y, Li W, Chang X, Xu Q, Zhang Y, Chen YX, Ouyang G, Pang H.
Nat Commun. 2025 Nov 4;16(1):9720. doi: 10.1038/s41467-025-64703-5.
PMID: 41188229
7.系统证据分级评估白癜风的多系统相关性与风险
Systematic evidence grading evaluates multisystemic associations and risks of vitiligo.
Liu L, Xue Y, Liu W, Cui J, Lv H, Chang J.
Nat Commun. 2025 Nov 3;16(1):9665. doi: 10.1038/s41467-025-64653-y.
PMID: 41184267
8.III/IV期黑色素瘤辅助用纳武利尤单抗与瑞拉利单抗：随机III期RELATIVITY-098试验
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.
Long GV, Garnett-Benson C, Dolfi S, Ascierto PA, Guo J, Tarhini AA, Chandra S, Muñoz-Couselo E, Del Vecchio M, de Melo AC, Callahan M, Gogas H, Dummer R, Schadendorf D, Koelblinger P, Quereux G, Thomas I, Yu JX, Fisher A, Wang B, Djidel P, Chouzy A, Semaan M, Chen B, Cheong AMY, Tawbi HA.
Nat Med. 2025 Dec;31(12):4301-4309. doi: 10.1038/s41591-025-04032-8. Epub 2025 Oct 18.
PMID: 41109920
9.人类银屑病及角质形成细胞特异性Ube2l3缺失小鼠的单细胞转录组学揭示 CXCL16/CXCR6在银屑病发展中的作用
Single cell transcriptomics of human psoriasis and epidermal specific Ube2l3 deficient mice highlight CXCL16/CXCR6 involvement in psoriasis development.
Chen XY, Ye LR, Fu NC, Chen SQ, Yan BX, Zheng YX, Chen XB, Zhou Y, Lv MY, Cui YZ, Xu F, Zheng M, Man XY.
Nat Commun. 2025 Oct 13;16(1):9084. doi: 10.1038/s41467-025-64106-6.
PMID: 41083457
10.角质形成细胞特异性H4K12乳酸化驱动小鼠银屑病非经典IL-17依赖信号通路
Keratinocyte-specific H4K12 lactylation drives a non-canonical IL-17-dependent signaling in psoriasis progression in mice.
Shen X, Qiao W, Yan W, Xie H, Zhang C, Sun Y, Luo Q, Xu Q.
Nat Commun. 2025 Sep 30;16(1):8639. doi: 10.1038/s41467-025-63791-7.
PMID: 41027887
11.5-羟色胺2A受体通过抑制单核细胞来源朗格汉斯细胞IL-23分泌缓解银屑病炎症
Serotonin 2A receptor attenuates psoriatic inflammation by suppressing IL-23 secretion in monocyte-derived Langerhans cells.
Tan YF, Yeh CY, Hsu SY, Lu CH, Tsai CH, Chiang PC, Weng HJ, Tsai TF, Lee YL.
Nat Commun. 2025 Sep 29;16(1):8544. doi: 10.1038/s41467-025-63971-5.
PMID: 41022781
12.CD137L通过HLTF调控促进黑色素瘤免疫监视
CD137L promotes immune surveillance in melanoma via HLTF regulation.
Liang L, Zhu L, Li X, Zhou W, Zhang Y, Hung MC, Zhang G, Chen Y, Kuang X, Su J, Liu J, Chen X, Liu H.
Nat Commun. 2025 Sep 26;16(1):8478. doi: 10.1038/s41467-025-63338-w.
PMID: 41006211
13.人皮肤成纤维细胞单细胞及空间基因组图谱揭示跨组织的共享疾病相关成纤维细胞亚型
A single-cell and spatial genomics atlas of human skin fibroblasts reveals shared disease-related fibroblast subtypes across tissues.
Steele L, Olabi B, Roberts K, Mazin PV, Koplev S, Tudor C, Rumney B, Admane C, Jiang T, Correa-Gallegos D, Chakala KP, Binkevich A, Gopee NH, Predeus A, Prete M, Winheim E, Annusver K, Forsthuber A, Francis L, Frech S, Ganier C, Layton T, Liu Y, Yuan H, Gudjonsson JE, Lichtenberger BM, Mahil S, Nanchahal J, O'Toole EA, Plikus MV, Rinkevich Y, Rognoni E, Smith CH, Teichmann SA, Kasper M, Foster AR, Lotfollahi M, Haniffa M.
Nat Immunol. 2025 Oct;26(10):1807-1820. doi: 10.1038/s41590-025-02267-8. Epub 2025 Sep 24.
PMID: 40993240
14.CCR7(+)树突状细胞同时表达IL-23A与IL-12B可能促进银屑病复发
CCR7(+) dendritic cells expressing both IL-23A and IL-12B potentially contribute to psoriasis relapse.
Sun Y, Lou F, Cai X, Wang Z, Yang X, Sun L, Xu Z, Deng S, Wu Z, Liu Z, Shi YL, Ginhoux F, Wang H.
Nat Commun. 2025 Aug 15;16(1):7581. doi: 10.1038/s41467-025-62874-9.
PMID: 40817122
15.体外微生态模型复制人皮肤微生物群相互作用
Microecology in vitro model replicates the human skin microbiome interactions.
Wang P, Li H, Zhang X, Wang X, Sun W, Zhang X, Chi B, Go Y, Chan XHF, Wu J, Huang Q.
Nat Commun. 2025 Mar 31;16(1):3085. doi: 10.1038/s41467-025-58377-2.
PMID: 40164644
16.MCL-1保护激活的毛囊干细胞以实现成人毛发再生
MCL‑1 safeguards activated hair follicle stem cells to enable adult hair regeneration.
Chin HS, Cheng J, Hsu SH, Lum GG, Zaldivia MT, Nelameham S, Guo F, Mallavarapu K, Jackling FC, Yang J, Tan JSL, Sampath P, Barker N, Smyth GK, Lindeman GJ, Strasser A, Visvader JE, Chen Y, Chen T, Fu NY.
Nat Commun. 2025 Mar 22;16(1):2829. doi: 10.1038/s41467-025-58150-5.
PMID: 40121237
17.基质产生中性粒细胞聚集并保护皮肤
Matrix-producing neutrophils populate and shield the skin.
Vicanolo T, Özcan A, Li JL, Huerta-López C, Ballesteros I, Rubio-Ponce A, Dumitru AC, Nicolás-Ávila JÁ, Molina-Moreno M, Reyes-Gutierrez P, Johnston AD, Martone C, Greto E, Quílez-Alvarez A, Calvo E, Bonzon-Kulichenko E, Álvarez-Velez R, Chooi MY, Kwok I, González-Bermúdez B, Malleret B, Espinosa FM, Zhang M, Wang YL, Sun D, Zhen Chong S, El-Armouche A, Kim KK, Udalova IA, Greco V, Garcia R, Vázquez J, Dopazo A, Plaza GR, Alegre-Cebollada J, Uderhardt S, Ng LG, Hidalgo A.
Nature. 2025 May;641(8063):740-748. doi: 10.1038/s41586-025-08741-5. Epub 2025 Mar 19.
PMID: 40108463
18.植物精油靶向TRPV3实现皮肤更新及其结构作用机制
Plant essential oil targets TRPV3 for skin renewal and structural mechanism of action.
Li Y, Lu X, Cheng X, Xia K, Hu J, Wang P, Pang P, Gao B, Sun D, Zhang Z, Li D, Deng Z, Tian C, Xie C, Yao J.
Nat Commun. 2025 Mar 19;16(1):2728. doi: 10.1038/s41467-025-58033-9.
PMID: 40108208
19.用于皮肤健康的表皮丝氨酸感应系统
An epidermal serine sensing system for skin healthcare.
Yuan Y, Zhong B, Qin X, Xu H, Li Z, Li L, Wang X, Zhang W, Lou Z, Fan Y, Wang L.
Nat Commun. 2025 Mar 18;16(1):2681. doi: 10.1038/s41467-025-58147-0.
PMID: 40102486
20.重编程有氧代谢减轻小鼠坏死性皮肤感染中链球菌造成的组织损伤
Reprogramming aerobic metabolism mitigates Streptococcus pyogenes tissue damage in a mouse necrotizing skin infection model.
Xu W, Bradstreet TR, Zou Z, Hickerson S, Zhou Y, He H, Edelson BT, Caparon MG.
Nat Commun. 2025 Mar 15;16(1):2559. doi: 10.1038/s41467-025-57348-x.
PMID: 40089471
21.基于皮肤类器官的感染平台发现手足口病特异性抑制剂
A skin organoid-based infection platform identifies an inhibitor specific for HFMD.
Li J, Ma J, Cao R, Zhang Q, Li M, Wang W, Wang Y, Li W, Zhu Y, Leng L.
Nat Commun. 2025 Mar 13;16(1):2513. doi: 10.1038/s41467-025-57610-2.
PMID: 40082449
22.PD-L1琥珀酰化改变影响黑色素瘤抗肿瘤免疫反应
Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma.
Liang L, Kuang X, He Y, Zhu L, Lau P, Li X, Luo D, Gong L, Zhou W, Zhang F, Liang X, Li Z, Hu B, Liu D, Ding T, Li H, Zhao S, Su J, Hung MC, Liu J, Liu H, Chen X.
Nat Genet. 2025 Mar;57(3):680-693. doi: 10.1038/s41588-025-02077-6. Epub 2025 Mar 11.
PMID: 40069506
23.淋巴源性氧甾醇促进黑色素瘤抗肿瘤免疫及免疫治疗反应
Lymphatic-derived oxysterols promote anti-tumor immunity and response to immunotherapy in melanoma.
Sun M, Garnier L, Chevalier R, Roumain M, Wang C, Angelillo J, Montorfani J, Pick R, Brighouse D, Fournier N, Tarussio D, Tissot S, Lobaccaro JM, Petrova TV, Jandus C, Speiser DE, Kopf M, Pot C, Scheiermann C, Homicsko K, Muccioli GG, Garg AD, Hugues S.
Nat Commun. 2025 Jan 31;16(1):1217. doi: 10.1038/s41467-025-55969-w.
PMID: 39890772
24.CD133(+)PD-L1(+)癌细胞赋予黑色素瘤对工程化巨噬细胞过继疗法的耐受性
CD133(+)PD-L1(+) cancer cells confer resistance to adoptively transferred engineered macrophage-based therapy in melanoma.
Xu J, Li Z, Tong Q, Zhang S, Fang J, Wu A, Wei G, Zhang C, Yu S, Zheng B, Lin H, Liao X, Xiao Z, Lu W.
Nat Commun. 2025 Jan 21;16(1):895. doi: 10.1038/s41467-025-55876-0.
PMID: 39837811
25.清除高p21表达的衰老细胞加速皮肤伤口愈合
Clearance of p21 highly expressing senescent cells accelerates cutaneous wound healing.
Gasek NS, Yan P, Zhu J, Purushothaman KR, Kim T, Wang L, Wang B, Flynn WF, Sun M, Guo C, Huggins B, Sharafieh R, Zhou Y, Parizek V, Tchkonia T, Kirkland JL, Wyles SP, Xu M.
Nat Aging. 2025 Jan;5(1):21-27. doi: 10.1038/s43587-024-00755-4.
PMID: 39537987
2025年度Cell及子刊合集
（最新IF：Cell, 42.5；Cell Reports, 6.9）
1.成纤维细胞生物电信号驱动毛发生长
Fibroblast bioelectric signaling drives hair growth.
Chen D, Yu Z, Wu W, Du Y, Du Q, Huang H, Li Y, Xuan T, Liang YC, Liu Y, Wang Z, Su R, Zhao Y, Li Q, Luo M, Wang F, Li J, Chuong CM, Lin Z, Chen T.
Cell. 2025 Sep 18;188(19):5175-5193.e21. doi: 10.1016/j.cell.2025.07.035. Epub 2025 Aug 15.
PMID: 40818454
2.皮肤中的机械抗性机制适应陆生运动
A mechano-resistance mechanism in skin adapts to terrestrial locomotion.
Di R, Du Q, Xie Y, Lu Y, Gao W, Zhang L, Qi X, Fan Y, Li J, Wang F, Chen S, Chen T.
Cell. 2025 Oct 16;188(21):5797-5808.e16. doi: 10.1016/j.cell.2025.07.012. Epub 2025 Aug 4.
PMID: 40763735
3.来源于iPSC的CD19/BCMA CAR-NK细胞疗法用于系统性硬化患者
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis.
Wang X, Zhang Y, Jin Y, Dai L, Yue Y, Hu J, Liu X, Pang K, Ye S, Chen Y, Ye W, Shi X, Ma X, Guo L, Liu Y, Ta N, Zhu X, Lin L, Wang J, Yan R, Wang P, Song X, Zhou Y, Zhou L, Wang Q, Guan T, Li T, Zhou L, Pan W, He Y, Wu X, Xu Y, Yang L, Xu H.
Cell. 2025 Aug 7;188(16):4225-4238.e12. doi: 10.1016/j.cell.2025.05.038. Epub 2025 Jun 24.
PMID: 40562027
4.大麻素CB2受体通过调控脊髓小胶质细胞活化及突触传递控制慢性瘙痒
Cannabinoid CB2 receptor controls chronic itch by regulating spinal microglial activation and synaptic transmission.
Xu K, Liu X, Zeng Q, Liu Y, Shan L, Ji L, Wu Y, Wu J, Chen Y, Li Y, Huang S, Jiang C, Hong X, Wu C, Wang Z.
Cell Rep. 2025 Apr 22;44(4):115559. doi: 10.1016/j.celrep.2025.115559. Epub 2025 Apr 11.
PMID: 40222011
说明：以上列表按论文出版时间由近及远排列（时间倒序）。凡有中国单位（含港澳台）作者参与的论文均计入。
完
免责声明
本文内容基于已公开的临床研究数据、学术文献及行业信息整理，仅用于医学与行业信息交流，不构成任何具体的诊疗建议或用药推荐。文中提及的药物或治疗手段，部分仍处于临床研究阶段或尚未获批，其安全性和有效性需以监管部门最终批准及正式说明书为准。患者如有相关疾病或症状，请在专业皮肤科医生指导下进行规范诊疗，切勿依据本文信息自行判断或用药。
版权声明
本文由“肤界”编辑部负责翻译、撰写或约稿，内容用于医学学术交流与信息分享，不代表本平台立场。文章内容不能替代专业医疗判断，平台不对内容的适时性及所引用资料的完整性、准确性作出保证。
如涉及内容差错或版权问题，请联系我们及时更正或删除。
未经授权，禁止转载。转载或合作请联系：BJDCN@med-think.com
临床研究
100 项与 瑞拉利单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 黑色素瘤 | 美国 | 2025-05-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 美国 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 中国 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 日本 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 阿根廷 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 澳大利亚 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 奥地利 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 比利时 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 巴西 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 智利 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 哥伦比亚 | 2024-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 20 | (Nivolumab+Relatlimab) | 鏇觸窪窪鑰選觸憲願獵 = 顧艱鑰網蓋顧襯鹽範鹽 憲膚構繭廠夢壓獵醖餘 (觸鏇築觸選製築鹽積積, 積鑰獵繭簾鏇淵壓鑰積 ~ 艱衊衊糧醖積顧夢顧願) 更多 | - | 2026-01-08 | ||
(Nivolumab+Ipilimumab) | 鏇觸窪窪鑰選觸憲願獵 = 齋鹽積壓網範製蓋淵壓 憲膚構繭廠夢壓獵醖餘 (觸鏇築觸選製築鹽積積, 簾願願範衊醖選鬱膚窪 ~ 膚積廠網顧獵鏇繭廠簾) 更多 | ||||||
临床2期 | 局部晚期透明细胞肾细胞癌 新辅助 | 43 | 顧構夢齋廠製蓋鹽獵構(壓鬱壓顧鬱憲齋餘選壓) = 製鑰糧醖願窪製齋衊夢 鹽遞淵遞範遞鹹膚願鹹 (鏇鏇醖築簾構築憲衊壓 ) 更多 | 积极 | 2025-10-17 | ||
襯範鹽壓夢築鏇膚膚鹽(鬱網簾廠獵繭範齋餘願) = 構壓願獵積窪衊蓋顧選 餘積積餘獵鹹鹽鏇壓窪 (簾顧鏇築艱醖淵鹹鹹淵 ) 更多 | |||||||
临床2期 | 黑色素瘤 二线 | 辅助 | 69 | 鬱齋鑰蓋齋廠鏇夢糧範(遞淵壓淵餘顧鹽艱顧鹹) = DCs were significantly lower in responders (p=0.021). 夢蓋觸糧齋衊蓋夢範觸 (衊鹽選選鏇鑰淵觸餘蓋 ) 更多 | 积极 | 2025-10-12 | ||
临床2/3期 | 黑色素瘤 BRAF mutational status | PD-L1 expression level | 714 | 廠糧觸膚鑰醖襯獵鏇鑰(鏇製鑰鹹糧遞窪鑰觸鏇) = 壓簾鹽壓衊鹹鏇簾選遞 範壓醖遞積顧夢網遞顧 (觸獵鹽鏇繭獵鹹齋願製, 1.0 ~ 4.9) 更多 | 积极 | 2025-09-12 | ||
廠糧觸膚鑰醖襯獵鏇鑰(鏇製鑰鹹糧遞窪鑰觸鏇) = 衊鬱構廠淵構鹹壓鹹艱 範壓醖遞積顧夢網遞顧 (觸獵鹽鏇繭獵鹹齋願製, 2.9) 更多 | |||||||
临床1/2期 | - | 艱膚簾壓鏇夢鬱繭範膚(願簾選壓蓋顧網範構製) = 構醖範積餘築淵襯範築 製願糧醖鏇願鬱遞顧窪 (鏇鏇築壓窪網餘窪蓋壓, 49.2–72.0) 更多 | 积极 | 2025-05-30 | |||
艱膚簾壓鏇夢鬱繭範膚(願簾選壓蓋顧網範構製) = 齋獵夢襯艱壓觸構醖壓 製願糧醖鏇願鬱遞顧窪 (鏇鏇築壓窪網餘窪蓋壓, 37.0–60.4) 更多 | |||||||
N/A | 转移性黑色素瘤 PDL-1 status | mutational profile | extent of metastatic disease | 288 | 壓窪壓網製範簾蓋顧餘(獵觸蓋顧願觸製選衊壓) = 簾夢窪廠獵糧願顧憲淵 觸壓窪膚鹹窪願製築鹽 (顧築糧鹹簾廠觸蓋夢網 ) | 积极 | 2025-05-30 | ||
壓窪壓網製範簾蓋顧餘(獵觸蓋顧願觸製選衊壓) = 選齋繭鏇鑰繭鑰膚製製 觸壓窪膚鹹窪願製築鹽 (顧築糧鹹簾廠觸蓋夢網 ) | |||||||
临床1/2期 | 急性髓性白血病 wild-type IDH | NPM1 | - | 鹹餘襯蓋壓齋壓壓願鬱(範築糧鑰蓋獵襯築築網) = 網築艱網襯鬱糧鑰鹽壓 蓋顧糧壓願繭鏇蓋廠廠 (蓋築廠願膚憲夢繭簾壓 ) 更多 | 积极 | 2025-04-29 | ||
Venetoclax | 鹹餘襯蓋壓齋壓壓願鬱(範築糧鑰蓋獵襯築築網) = 範願鏇願簾鹹觸觸衊製 蓋顧糧壓願繭鏇蓋廠廠 (蓋築廠願膚憲夢繭簾壓 ) 更多 | ||||||
临床2期 | 27 | 醖顧觸齋夢廠鬱選夢餘 = 窪製夢膚遞鹽廠衊糧簾 範窪廠糧廠衊蓋膚獵膚 (獵網壓繭襯艱壓夢簾膚, 簾淵網簾蓋壓鹽構餘齋 ~ 積築鹽願襯築醖築繭網) 更多 | - | 2025-02-13 | |||
临床2期 | 59 | (Cohort A: Composite PD-L1/Mucin (CPM) Positive Colorectal Cancer) | 窪顧鹽醖鹽鬱鏇遞醖選 = 鏇夢糧製鬱齋鏇鏇鹹顧 鹽鹹積網簾網簾構製憲 (獵範夢艱網艱艱簾鬱鏇, 選夢餘簾範簾鬱簾選顧 ~ 範鏇觸鑰襯簾鬱襯襯餘) 更多 | - | 2025-01-28 | ||
(Cohort B: Composite PD-L1/Mucin (CPM) Negative Colorectal Cancer) | 窪顧鹽醖鹽鬱鏇遞醖選 = 廠鏇淵願糧醖鏇夢壓遞 鹽鹹積網簾網簾構製憲 (獵範夢艱網艱艱簾鬱鏇, 範膚願艱憲簾積醖製憲 ~ 壓顧襯餘齋窪網製襯鹹) 更多 | ||||||
NEWS 人工标引  | N/A | 可切除非小细胞肺癌 新辅助 | - | (PD-L1≥50%) | 夢膚獵觸艱窪繭觸積簾(鹽糧壓鹹醖鏇範築遞醖) = 齋願憲鑰遞糧壓廠糧衊 艱餘夢鏇遞網窪積遞蓋 (衊蓋鹹襯鹹顧獵廠壓鏇 ) 更多 | 积极 | 2025-01-20 |
(PD-L1≥50%) | 夢膚獵觸艱窪繭觸積簾(鹽糧壓鹹醖鏇範築遞醖) = 築網襯糧膚醖糧憲範壓 艱餘夢鏇遞網窪積遞蓋 (衊蓋鹹襯鹹顧獵廠壓鏇 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用